(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/32014 A2

(51) International Patent Classification[7]: A01N

(21) International Application Number: PCT/US00/30191

(22) International Filing Date: 1 November 2000 (01.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/431,705 1 November 1999 (01.11.1999) US

(71) Applicant: ORAVAX, INC. [US/US]; 38 Sidney Street, Cambridge, MA 02139-4169 (US).

(72) Inventors: KLEANTHOUS, Harold; 89 Madison Avenue, Newtonville, MA 02160 (US). LONDONO-ARCILA, Patricia; Flat B, 11 Beckwith Road, London SE24 9LH (GB). FREEMAN, Donna; 68 Thorpe Way, Cambridge CB5 8UB (GB).

(74) Agent: MICHAUD, Susan, M.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF SALMONELLA VECTORS FOR VACCINATION AGAINST HELLICOBACTER INFECTION



(57) Abstract: The invention provides a method of immunization against Helicobacter, involving mucosal administration of an attenuated Salmonella vector including a nucleic acid molecule encoding a Helicobacter antigen, and parenteral administration of a soluble Helicobacter antigen, co-administered with a suitable parenteral adjuvant. Also provided by the invention are attenuated Salmonella vectors for use in this method.

WO 01/32014 A2

USE OF SALMONELLA VECTORS FOR VACCINATION AGAINST HELICOBACTER INFECTION

Background of the Invention

This invention relates to the use of Salmonella vectors in vaccination methods against Helicobacter infection.

Helicobacter is a genus of spiral, gram-negative bacteria that colonize the gastrointestinal tracts of mammals. Several species colonize the stomach, most notably *H. pylori, H. heilmanii, H. felis*, and *H. mustelae*. Although *H. pylori* is the species most commonly associated with human infection, *H. heilmanii* and *H. felis* have also been isolated from humans, but at lower frequencies than *H. pylori*. Helicobacter infects over 50% of adult populations in developed countries and nearly 100% in developing countries and some Pacific rim countries, making it one of the most prevalent infections worldwide.

Helicobacter is routinely recovered from gastric biopsies of humans with histological evidence of gastritis and peptic ulceration. Indeed, *H. pylori* is now recognized as an important pathogen of humans, in that the chronic gastritis it causes is a risk factor for the development of peptic ulcer diseases and gastric carcinoma. It is thus highly desirable to develop safe and effective methods for preventing and treating Helicobacter infection.

Summary of the Invention

The invention provides a method of inducing an immune response against Helicobacter in a mammal. This method involves mucosally (*e.g.*, orally) administering to a mammal (*e.g.*, a human) an attenuated Salmonella (*e.g.*, *S. typhi* (*e.g.*, CVD908-htrA or CVD908) or *S. typhimurium* (*e.g.*,

BRD509 or BRD807)) vector including a nucleic acid molecule encoding a Helicobacter antigen (*e.g.*, a urease, a urease subunit, or an immunogenic fragment thereof), and parenterally administering to the mammal a Helicobacter antigen (*e.g.*, a urease, a urease subunit, or an immunogenic fragment thereof), optionally, in association with an adjuvant, such as an aluminum compound (*e.g.*, alum). The nucleic acid molecule encoding the Helicobacter antigen can be under the control of a promoter, such as an *htrA* or a *nirB* promoter. The antigen used in the mucosal administration can be different from, cross-reactive with, or, preferably, identical to the parenterally administered antigen. In a preferred embodiment, the mucosal administration primes an immune response to an antigen, and the parenteral administration boosts an immune response to the antigen. A mammal treated according to the method of the invention can be at risk of developing, but not have, a Helicobacter infection, or can have a Helicobacter infection. That is, the method can be used to prevent or to treat Helicobacter infection.

The invention also includes use of the Salmonella vectors described above in the preparation of medicaments for preventing or treating Helicobacter (*e.g.*, *Helicobacter pylori*) infection by mucosal (*e.g.*, oral) administration of the vectors, and parenteral administration of a Helicobacter antigen (*e.g.*, a urease, a urease subunit, or an immunogenic fragment thereof; also see other antigens listed herein), optionally in association with an adjuvant (*e.g.*, alum).

The invention also provides an attenuated Salmonella (*e.g.*, *S. typhi* (*e.g.*, CVD908-htrA or CVD908) or *S. typhimurium* (*e.g.*, BRD509 or BRD807)) vector including a nucleic acid molecule encoding a Helicobacter antigen, *e.g.*, a urease, a urease subunit, or an immunogenic fragment thereof, expressed as a fusion protein that can be selectively

targeted to the outer membrane or secreted from the cell. The nucleic acid molecule encoding the Helicobacter antigen can be under the control of a promoter, such as an *htrA* or a *nirB* promoter.

Other features and advantages of the invention will be apparent from the following detailed description, the drawings, and the claims.

Brief Description of the Drawings

Fig. 1 is a schematic representation of an expression plasmid (pH/NUR3) used in Salmonella immunizations.

Fig. 2A is a graph showing the urease-specific serum antibody (IgG2a) response of mice that were mucosally primed with *S. typhimurium*-vectored urease, followed by parenteral boosting with urease and alum.

Fig. 2B is a graph showing the T helper phenotype (IgG1/IgG2a ratio) of mice that were mucosally primed with *S. typhimurium*-vectored urease, followed by parenteral boosting with urease and alum.

Fig. 3A is a graph showing protection against Helicobacter infection in mice that were mucosally primed with *S. typhimurium*-vectored urease, followed by parenteral boosting with urease and alum.

Fig. 3B is a table showing protection against Helicobacter infection in mice that were mucosally primed with *S. typhimurium*-vectored urease, followed by parenteral boosting with urease and alum, as $\log_{10}$ reduction in comparison to a no treatment control group.

Fig. 4 provides the nucleic acid sequence (SEQ ID NOs:1 and 19) and amino acid sequence (SEQ ID NOs:2-18 and 20-30) of plasmid pHUR3.

Fig. 5 is a schematic representation of some relevant features of pHUR3.

Detailed Description

This invention provides an immunization method against Helicobacter infection that involves: (i) mucosal administration of an attenuated Salmonella vector containing a nucleic acid molecule encoding a Helicobacter antigen, and (ii) parenteral administration of a Helicobacter antigen, preferably, in association with an adjuvant. The method can be used to prevent or to treat Helicobacter infection in a mammal, such as a human. Also, the mucosal administration can be used to prime an immune response to an antigen, and the parenteral administration can be used to boost an immune response to the antigen. The invention also provides Salmonella vectors for use in this method. Salmonella vectors, Helicobacter antigens, and adjuvants that can be used in the method of the invention are first described, as follows. Then, details of the immunization method of the invention, and examples of its efficacy, are provided.

Salmonella Vectors

Numerous attenuated Salmonella vectors that can be used in the invention are known in the art, and can be derived from species such as, for example, *S. typhi*, *S. typhimurium*, *S. enteritidis*, *S. dublin*, *S. minnesota*, and *S. choleraesuis*. The vectors can be attenuated chemically (*e.g.*, Ty21a, Swiss Serums and Vaccines, Berna Products) or, preferably, by genetic mutagenesis (*e.g.*, Ty800). For example, attenuation can be achieved by inactivation of key regulatory genes or genes necessary for *in vivo* survival. For example, the following genes can be inactivated: *cya*, *crp*, and *asd* (cAMP metabolism; see, *e.g.*, Curtiss *et al.*, Vaccine 6:155-160, 1988; Nakayama *et al.*, BioTechnology 6:693, 1988; WO 92/11361), adenylate cyclase and the cAMP receptor (U.S. Patent No. 5,389,368), *cdt* (invasion of liver and spleen), *phoP/phoQ* (two component regulator; see, *e.g.*, Fields

et al., Science 243:1059-1062, 1989; U.S. Patent No. 5,424,065), *ompR* (control of capsule and porin expression; see, *e.g.*, Dorman *et al.*, Infection and Immunity 57:2136-2140, 1989), outer membrane proteins (U.S. Patent No. 5,527,529), reverse mutants of streptomycin mutants (U.S. Patent No. 4,350,684), genes in pathogenicity islands (Shea *et al.*, Infection and Immunity 67:213-219, 1999; WO 99/37759), *SPI-2* (invasion of Peyer's patches), *Dam* (DNA methylation), *htrA* (heat shock protein; U.S. Patent No. 5,804,194), and other heat shock proteins (U.S. Patent No. 5,804,194). The vectors can also be attenuated by auxotrophic mutations, such as mutations in any of the *aroA*, *aroC*, *aroD* (aromatic compounds), *purA*, or *guaAB* (purines) genes (see, *e.g.*, U.S. Patent No. 5,770,214).

Preferably, the mutations in the Salmonella strains used in the invention are non-reverting mutations, *i.e.*, mutations that cannot be repaired in a single step. Mutations of this sort include deletions, inversions, insertions, and substitutions. Preferably, there is more than one mutation in the vector. Methods of making such mutations are well known in the art.

Specific examples of Salmonella vectors that can be used in the invention include *S. typhi* mutant strains, for example, CVD908 *S. typhi* Ty2 ΔaroC/ΔaroD (Hone *et al.*, Vaccine 9:810-816, 1991), CVD908-htrA *S. typhi* Ty2 ΔaroC/ΔaroD/ΔhtrA (Tacket *et al.*, Infection and Immunity 65:452-456, 1997), BRD1116 *S. typhi* Ty2 ΔaroA/ΔaroC/ΔhtrA (Lowe *et al.*, Infection and Immunity 67:700-707, 1999), *S. typhi* ΔaroA/ΔaroE (U.S. Patent No. 5,770,214; deposited at PHLS, NCTC, 61 Colindale Avenue, London NW9 5HT under Accession No. NCTC 12164), *S. typhi* Ty2 ΔaroA/ΔaroC Km-R (U.S. Patent No. 5,770,214; deposited at PHLS, NCTC, 61 Colindale Avenue, London NW9 5HT under Accession No. NCTC 12165), and *S. typhi* ΔaroA/ΔaroD (U.S. Patent No. 5,770,214;

deposited at PHLS, NCTC, 61 Colindale Avenue, London NW9 5HT under Accession No. NCTC 122309). It has been shown that one of these, CVD908-htrA, is safe and immunogenic in phase I (Tacket *et al.*, Infection and Immunity 65:452-456, 1997) and phase II studies in a total of 100 adult volunteers.

Specific examples of *S. typhimurium* mutant strains that can be used in the invention include BRD509 *S. typhimurium* ΔaroA/ΔaroD (Strugnell *et al.*, Infection and Immunity 60:3994-4002, 1992), BRD807 *S. typhimurium* ΔaroA/ΔhtrA (Chatfield *et al.*, Microbial Pathogenesis 12:145-151, 1992; U.S. Patent No. 5,804,194; deposited at PHLS, NCTC, 61 Colindale Avenue, London NW9 5HT under Accession No. NCTC 12459), BRD698 (U.S. Patent No. 5,804,194; deposited at PHLS, NCTC, 61 Colindale Avenue, London NW9 5HT under Accession No. NCTC 12457), and BRD726 (U.S. Patent No. 5,804,194; deposited at PHLS, NCTC, 61 Colindale Avenue, London NW9 5HT under Accession No. NCTC 12458).

Additional examples of Salmonella mutant strains that can be used in the invention are described in the following publications: double *aro* mutants (WO 89/05856, U.S. Patent No. 5,770,214), *htrA* mutants (WO 91/15572, U.S. Patent No. 5,804,194), and *ompR* mutants (U.S. Patent No. 5,527,529). Also see, for example, Nakayama *et al.*, BioTechnology 6:693, 1988 and WO 92/11361. In addition, there are numerous alternative strains of *S. typhi* and *S. typhimurium* described in the literature or known in the art that are also attenuated in their virulence, and have been shown to induce immune responses against heterologous antigens. Any of these strains can be used in the method of the present invention.

Any of the attenuated Salmonella strains described above, or others, can be used in the method of the invention to administer a Helicobacter antigen to a mammal for vaccination against Helicobacter infection. This can be accomplished by introducing into the attenuated Salmonella strain a nucleic molecule encoding a Helicobacter antigen. The antigen-encoding nucleic acid molecule to be introduced into the attenuated Salmonella strain can be present, for example, in a plasmid vector (*e.g.*, pHUR3, pHUR4, pNUR3, or pNUR4 (see below)) that includes a regulatory sequence, such as a promoter, and, optionally, a sequence encoding a secretion signal (*e.g.*, a bacterial hemolysin (hly) secretion signal; WO 87/06953, U.S. Patent No. 5,143,830).

The promoter can be a prokaryotic promoter, for example, a Salmonella promoter, which directs expression of the Helicobacter antigen in the Salmonella vector. Examples of such promoters include the *htrA* promoter (WO 95/20665), the *nirB* promoter (WO 92/15689, U.S. Patent No. 5,547,664), the *ssaH* promoter (Valdivia *et al.*, Science 277:2007-2011, 1997), the *ompR* promoter, and any other Salmonella or other bacterial promoter that is upregulated when Salmonella is taken up by mammalian cells. Alternatively, the promoter can be a eukaryotic promoter, such as the cytomegalovirus promoter. Use of such promoters allows for expression of target antigen in a eukaryotic cell, with Salmonella acting as the delivery vehicle for this DNA immunization approach. The construction of such vectors is known in the art. Of course, numerous eukaryotic promoters are known in the art and can be used in the invention.

Introduction of a plasmid into an attenuated Salmonella strain can be accomplished using any of a number of standard methods, such as electroporation or bacteriophage transduction (Turner *et al.*, Infection and Immunity 61:5374-5380, 1993). Also see, *e.g.*, Ausubel *et al.*, *Current*

Protocols in Molecular Biology, John Wiley & Sons Inc., 1994, and Ward *et al.*, Infection and Immunity 67(5):2145-2152, 1999, for methods of introducing plasmids into bacteria, such as Salmonella.

Helicobacter Antigens

Preferred antigens for use in the invention are Helicobacter (*e.g.*, *H. pylori* or *H. felis*) proteins (*i.e.*, peptides or polypeptides), other components Helicobacter (*e.g.*, lipopolysaccharides, carbohydrates, or nucleic acid molecules), or immunogenic fragments thereof. Preferably, the same or a similar (*e.g.*, a fragment) antigen is used in the mucosal administration step as in the parenteral administration step, however, the antigen used in each of these steps can differ. Also, preferably, the mucosally administered antigen primes an immune response to the antigen, and the parenterally administered antigen boosts an immune response to the same antigen. For the mucosal administration step, a nucleic acid molecule (*e.g.*, a DNA molecule) encoding a desired antigen is inserted into an attenuated Salmonella vector, as is described above. For the parenteral administration step, the antigen can be, for example, purified from a bacterial culture or produced using standard recombinant or chemical synthetic methods. Methods for identifying immunogenic fragments of polypeptide antigens are known in the art, and can be employed in preparing antigens for use in the method of the invention (see, *e.g.*, Sturniolo *et al.*, Nature Biotechnology, "Generation of Tissue-Specific and Promiscuous HLA Ligand Databases Using DNA Microarrays and Virtual HLA Class II Matrices," June, 1999). Additional antigens that can be used in the parenteral administration step are whole Helicobacter bacteria and non-purified protein preparations, such as Helicobacter lysates.

The antigens used in the invention can be produced as fusion proteins, which are polypeptides containing amino acid sequences corresponding to two or more proteins (or fragments thereof) that are normally separate proteins, linked together by a peptide bond(s). Fusion proteins generally are synthesized by expression of a hybrid gene, containing nucleotides encoding each of the individual polypeptides that make up the fusion protein. An example of an antigenic fusion protein that can be used in the invention is one that contains a cholera toxin (CT) or an *E. coli* heat-labile toxin (LT) adjuvant (*e.g.*, a toxin A or B subunit, or a fragment or derivative thereof having adjuvant activity) fused to an *H. pylori* antigen, *e.g.*, a urease antigen. Another type of fusion protein included in the invention consists of an antigen fused to a polypeptide (*e.g.*, glutathione S-transferase (GST)) that facilitates purification of the fusion protein. Still another type of fusion protein that can be used in the invention is a fusion with a polypeptide that targets the expressed protein to cells of the immune system. For example, fusions with CD4 or Staph A can be used. Proteins used as antigens in the invention can also be covalently coupled or chemically cross-linked to adjuvants, using standard methods.

The most preferred *H. pylori* antigens for use in the invention are urease antigens, which include, *e.g.*, immunogenic fragments or subunits (*e.g.*, UreA or UreB) of urease. Most preferred urease antigens are enzymatically inactive, recombinant multimeric urease complexes, produced as described in Lee *et al.*, WO 96/33732. A number of other immunogenic *H. pylori* antigens can be administered according to the invention, *e.g.*, catalase (WO 95/27506), HspA and HspB (WO 94/26901), lactoferrin receptor (WO 97/13784), p76 (WO 97/12908), p32 (WO 97/12909), BabA and BabB (WO 97/47646), AlpA (WO 96/41880), AlpB (WO 97/11182), as well as the antigens described in WO 96/38475, WO

96/40893, WO 97/19098, WO 97/37044, WO 98/18323, WO 97/37044, WO 97/4764, WO 98/04702, and WO 98/32768. Additional preferred antigens for use in the invention are GHPO 1516, GHPO 789, GHPO 386, GHPO 1615, GHPO 1360, GHPO 1320, GHPO 639, GHPO 792, GHPO 536, GHPO 525, GHPO 1275, GHPO 1688, GHPO 706, GHPO 419, GHPO 1595, GHPO 1398, GHPO 986, GHPO 1282, GHPO 1056, GHPO 1443, GHPO 13, GHPO 109, GHPO 257, GHPO 1034, GHPO 236, GHPO 1166, GHPO 1351, and GHPO 1420 (WO 98/21225, WO 98/43478, and WO 98/43479), as well as other antigens described in these publications.

Adjuvants

Although not required, the attenuated Salmonella vectors described above for mucosal administration step can be administered with a mucosal adjuvant. The adjuvant can be admixed with the Salmonella vector or expressed in the Salmonella vector (*e.g.*, as a fusion protein with an antigen, see above), either from an integrated nucleic acid molecule or episomally, *e.g.*, on a plasmid. Such adjuvants can be chosen from bacterial toxins, *e.g.*, the cholera toxin (CT), the *E. coli* heat-labile toxin (LT), the *Clostridium difficile* toxin, and the Pertussis toxin (PT), or combinations, subunits, toxoids, fragments, homologs, derivatives, fusions, or mutants that are derived therefrom and have adjuvant activity. For example, it is possible to use a purified preparation of the native cholera toxin B subunit (CTB) or a polypeptide including the carboxyl-terminal repeats of *C. difficile* toxin A (WO 97/02836). Preferably, a mutant is used in which toxicity is reduced. Such mutants are described in, *e.g.*, WO 95/17211 (mutant CT Arg-7-Lys), WO 96/6627 (mutant LT Arg-192-Gly), and WO 95/34323 (mutant PT Arg-9-Lys and Glu-129-Gly). Other LT mutants that can be used include at least one of the following mutations: Ser-63-Lys, Ala-69-Gly,

Glu-110-Asp, and Glu-112-Asp. Other compounds, such as MPLA, PLGA, and QS-21, can also be used as adjuvants for the mucosal route.

Adjuvants for use in parenteral administration include, for example, aluminum compounds (*e.g.*, alum), such as aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphate. The antigen can be precipitated with, or adsorbed onto, the aluminum compound using standard methods.

In addition to aluminum compounds, a large number of appropriate adjuvants for administration by the systemic or parenteral route exist in the art and can be used in the invention. For example, liposomes; ISCOMS; microspheres; protein chochleates; vesicles consisting of nonionic surfactants; cationic amphiphilic dispersions in water; oil/water emulsions; muramidyldipeptide (MDP) and its derivatives, such as glucosyl muramidyldipeptide (GMDP), threonyl-MDP, murametide, and murapalmitin; QuilA and its subfractions; as well as various other compounds, such as DC-chol; monophosphoryl-lipid A (MPLA) major lipopolysaccharide from the wall of a bacterium, for example, *E. coli*, *S. minnesota*, *S. typhimurium*, *Shigella flexneri*, or *N. meningitidus*; algan-glucan; gamma-inulin; calcitriol; and loxoribine can be used. Other adjuvants, such as RIBI (ImmunoChem, Hamilton, MT) and polyphosphazene (WO 95/2415), can also be used in parenteral administration.

Useful liposomes for the purposes of the present invention can be selected, for example, from pH-sensitive liposomes, such as those formed by mixing cholesterol hemisuccinate (CHEMS) and dioleyl phosphatidyl ethanolamine (DOPE); liposomes containing cationic lipids recognized for their fusiogenic properties, such as 3-beta-(N-(N',N'-dimethylamino-ethane)carbamoyl)cholesterol (DC-chol) and its equivalents, which are

described in U.S. Patent No. 5,283,185 and WO 96/14831; dimethyldioctadecylammonium bromide (DDAB) and the BAY compounds described in EP 91645 and EP 206 037, for example, Bay R1005 (N-(2-deoxy-2-L-leucylamino-beta-D-glucopyranosyl)-N-octa-decyldodecanoylamide acetate; and liposomes containing MTP-PE, a lipophilic derivative of MDP (muramidyldipeptide). These liposomes are useful as adjuvants with all of the antigens described herein.

Useful ISCOMs for the purposes of the present invention can be selected, for example, from those compounds of QuilA or of QS-21 combined with cholesterol and, optionally, also with a phospholipid, such as phosphatidylcholine. These are particularly advantageous for the formulation of the lipid-containing antigens.

Useful microspheres for the purposes of the present invention can be formed, for example, from compounds such as polylactide-co-glycolide (PLAGA), alginate, chitosan, polyphosphazene, and numerous other polymers.

Useful protein chochleates for the purposes of the present invention can be selected, for example, from those formed from cholesterol and, optionally, an additional phospholipid, such as phosphatidylcholine. These are especially advantageous for the formulation of the lipid-containing antigens.

Useful vesicles consisting of nonionic surfactants for the purposes of the present invention can be, for example, formed by a mixture of 1-mono-palmitoyl glycerol, cholesterol, and dicetylphosphate. They are an alternative to conventional liposomes, and can be used for the formulation of all of the antigens described herein.

Useful oil/water emulsions for the purposes of the present invention can be selected, for example, from MF59 (Biocine-Chiron), SAF1 (Syntex), and the montanides ISA51 and ISA720 (Seppic).

A useful adjuvant for the purposes of the present invention can also be a fraction derived from the bark of the South American tree *Quillaja Saponaria Molina*, for example, QS-21, a fraction purified by HPLC chromatography as is described in U.S. Patent No. 5,057,540. Since some toxicity may be associated with QS-21, it may be advantageous to use it in liposomes based on sterol, as is described in WO 96/33739.

Induction of an Immune Response Against Helicobacter

The method of the invention can be used to prevent Helicobacter infection in a patient, as well as to treat an ongoing Helicobacter infection in a patient. Thus, gastroduodenal diseases associated with these infections, including acute, chronic, or atrophic gastritis, and peptic ulcers, *e.g.*, gastric or duodenal ulcers, can be prevented or treated using the method of the invention.

As is noted above, the method of the invention involves mucosal (*e.g.*, oral, intranasal, intragastric, pulmonary, intestinal, rectal, ocular, vaginal, or urinary tract) administration of a Salmonella vector including a nucleic acid molecule that encodes a Helicobacter antigen, followed by parenteral (*e.g.*, intramuscular, subcutaneous, intradermal, intraepidermal, intravenous, or intraperitoneal) administration of a Helicobacter antigen, preferably in association with an adjuvant. The antigen used in the mucosal prime can be different from, cross-reactive with, or, preferably, identical to the parenterally administered antigen. Preferably, the mucosal administration step primes an immune response to an antigen, and the parenteral administration step boosts an immune response to the antigen.

Also included in the invention are vaccination methods involving parenteral priming and mucosal boosting (*e.g.*, with a Salmonella vector including a nucleic acid molecule encoding a Helicobacter antigen), and parenteral administration of a Salmonella vector including a nucleic acid molecule encoding a Helicobacter antigen.

Attenuated Salmonella vectors, antigens, formulations, adjuvants, administration regimens, specific mucosal and parenteral routes, and dosages to be used in the method of the invention can readily be determined by one skilled in the art. For example, 5×10^6 - 5×10^{10} colony forming units, *e.g.*, 5×10^8 colony forming units, of an attenuated Salmonella vector can be used in the mucosal administration, and 5-1000 µg, *e.g.*, 100 µg, antigen, can be used in the parenteral administration. The mucosal administration can take place only once or two or more (*e.g.*, three, four, or five) times, for example, separated by two, three, or four days or weeks. Similarly, the parenteral administration can take place once or two or more (*e.g.*, three, four, or five) times, separated by weeks, months, or years from each other or the mucosal administration.

In one example of an immunization regimen that can be used, a patient is primed with two doses of an attenuated Salmonella vector (*e.g.*, *S. typhi* CVD908-htrA or CVD908, or *S. typhimurium* BRD509 or BRD807) expressing an antigen (*e.g.*, urease from plasmid pHUR3, pHUR4, pNUR3, or pNUR4) on days 0 and 21, and then parenterally boosted on day 51 or later with an antigen (*e.g.*, urease) and an adjuvant (*e.g.*, alum). The details of construction of pHUR3 and pNUR3, which each include an ampicillin resistance gene, are described below. pHUR4 and pNUR4 are constructed by removing the ampicillin resistance gene from pHUR3 and pNUR3, respectively, by digestion with the restriction endonuclease *RcaI*, and

cloning into the digested vectors a kanamycin resistance gene that can be obtained from plasmid pUC4K (Pharmacia) by digestion with *EcoRI.*

A useful pharmaceutical composition for the purposes of the present invention can be manufactured in a conventional manner. In particular, it can be formulated with a pharmaceutically acceptable carrier or diluent, *e.g.*, water or a saline solution. In general, the diluent or carrier can be selected according to the mode and route of administration and according to standard pharmaceutical practices. Appropriate carriers or diluents, as well as what is essential for the preparation of a pharmaceutical composition, are described, *e.g.*, in *Remington's Pharmaceutical Sciences* (18^{th} edition), ed. A. Gennaro, 1990, Mack Publishing Company, Easton, PA., a standard reference book in this field. As a specific example, the attenuated Salmonella vectors of the invention can be formulated in a tablet for oral administration (see, *e.g.*, U.S. Patent No. 5,804,194).

The therapeutic or prophylactic efficacy of the method of the invention can be evaluated according to standard methods, *e.g.*, by measuring the induction of an immune response or the induction of therapeutic or protective immunity using, *e.g.*, the mouse/*H. felis* model and the procedures described in Lee *et al.*, Eur. J. Gastroenterology and Hepatology 7:303, 1995 or Lee *et al.*, J. Infect. Dis. 172:161, 1995. Persons skilled in this art will realize that *H. felis* can be replaced in the mouse model by another Helicobacter species. For example, the efficacy of the method is, preferably, evaluated in a mouse model using an *H. pylori* strain adapted to mice. The efficacy can be determined by comparing the level of infection in gastric tissue (*e.g.*, by measuring the urease activity, bacterial load, or condition of the gastritis) with that in a control group. A therapeutic effect or a protective effect exists when infection is reduced

compared with a control group. Experimental methods and results showing the efficacy of the present method is described as follows.

Experimental methods and results

Construction of ureAB expression plasmids under the control of the nirB and htrA promoters - Method 1

A *ureAB* expression plasmid is constructed by subcloning a PCR product containing the *ureAB* genes (amplified from plasmid pORV273) into plasmid vector ptetnir15. Plasmid pORV273 is obtained from OraVax, Inc., Cambridge, MA. Plasmid ptetnir15 has been described (Chatfield *et al.*, Bio/Technology 10:888-892, 1992; Oxer *et al.*, Nucl. Acids Res. 19:1889-1892, 1991). This vector was modified by standard techniques known in the art, to introduce into the vector a suitable restriction site for subcloning other genes for optimal expression under control of the *nirB* promoter. An *Nco*I site was introduced 10 basepairs 3' to the Shine-Dalgarno sequence of ptetnir15, and the resultant plasmid is designated ptetnir15/mod. Plasmid ptetnir15/mod, carried in strain BRD940, is obtained from Peptide Therapeutics Ltd., Cambridge, U.K.

The *ureAB* gene is amplified by PCR from pORV273 using Turbo Pfu polymerase (Stratagene), which has 3'-5' proof-reading activity, and two primers, designated orafor and orarev. Primer orafor introduces *Eco*RI and *Bsp*HI sites immediately upstream of the initiating codon of the *ureA* gene. Primer orarev binds approximately 18 basepairs downstream of the *Bam*HI site that is located 45 basepairs downstream of the termination codon of the *ureB* gene.

The PCR reaction includes 0.1 μg pORV273 and 100 pmol each of primers orafor (5'-TAG GGA ATT CTC ATG AAA CTC ACC CCA AAA G-3' (SEQ ID NO:31)) and orarev (5'-GCC AAC TTA GCT TCC TTT

CGG G-3' (SEQ ID NO:32)) per 100 μl reaction and utilizes 25 cycles, with an annealing temperature of 50°C. The resulting 2.4 kb PCR product is purified from a 1% agarose gel using a Qiaquick gel extraction kit (Qiagen). As is described below, the actual method used in the generation of pNUR and pHUR differed from this description in the sequence of orarev. Therefore, the method described here may need to be adapted in ways known to those skilled in the art by changing, for example, the precise annealing temperature or the number of cycles required to give sufficient product, or even in the sequence of the primer orarev.

The PCR product is digested with *Bsp*HI + *Bam*HI, and purified with a Promega Wizard DNA clean-up kit. Plasmid ptetnir15/mod is digested with *Nco*I + *Bam*HI (the *Nco*I site is 10 basepairs 3' to the Shine-Dalgarno sequence of ptetnir15, and generates a cohesive end that is compatible with *Bsp*HI), and dephosphorylated using shrimp alkaline phosphatase. The largest fragment from the digestion of ptetnir15/mod is isolated from a 1% agarose gel using a Qiaquick gel extraction kit (Qiagen), and ligated to the digested PCR product using the Ligator Express Kit (Clontech). Ligations are transformed into electrocompetent *E. coli* TG1 cells (Stratagene).

Plasmids from ampicillin-resistant transformants are screened for the presence of the full length, 2.4 kb *ureAB* gene by restriction analysis. The *ureAB* gene from plasmid pORV273 has a *Bam*HI site within the coding sequence. However, in a small number of ptetnir15/mod + *ureAB* transformants, incomplete digestion or re-ligation of the two *ureAB* fragments yields the full length *ureAB* PCR product. The orientation of the *ureAB* gene in the ptetnir15-derived plasmid is confirmed by PCR, and a plasmid with the full length *ureAB* gene, in the correct orientation is designated pNUR.

The *nirB* promoter in plasmid pNUR is replaced with the *htrA* promoter from phtrAcore, which is obtained from Peptide Therapeutics Ltd., Cambridge, U.K. Plasmids pNUR and phtrAcore are digested with *Pst*I and *Bgl*II. Digested pNUR is dephosphorylated with shrimp alkaline phosphatase. The digestion products are run on a 1% agarose gel, and a 0.8 kb fragment containing the *htrA* promoter from the phtrAcore digestion and the 4.0 kb fragment from pNUR lacking the *nirB* promoter are extracted from the gel using a Qiagen Qiaquick gel extraction kit. The two fragments are ligated together (Clontech Ligator express kit), and transformed into electrocompetent *E. coli* TG1 cells (Stratagene). Transformants are screened for the presence of the *htrA* promoter by PCR using primer pairs specific for *htrA* (5902/5904) or *nirB* (5901/5904). A plasmid with the *htrA* promoter and a full length *ureAB* gene is designated pHUR.

The nucleotide sequence across the promoter region and *ureAB* genes of final plasmids are confirmed. Samples of the plasmids are prepared using the Qiagen "Plasmid midi kit" (Catalog No. 12143), and the DNA sequence determined by standard techniques. Oligonucleotides 5901 to 5919 (see below) can be used, and allow nucleotide sequence determination of both DNA strands. Oligonucleotides 5901 and 5902 hybridize within *nirB* and *htrA*, respectively, while 5919 hybridizes within ptetnir15/mod, downstream of the *ureAB* genes. The other oligonucleotides hybridize within the *ureAB* genes. The data confirm that the nucleotide sequence across the recombinant region of all plasmids are as expected.

Plasmids pNUR and pHUR are introduced into *S. typhimurium* strains such as, *e.g.*, BRD509 and BRD807, and *S. typhi* strains such as, *e.g.*, CVD908 and BRD948, by electroporation and selection of ampicillin-resistant colonies.

Construction of ureAB expression plasmids under the control of the nirB and htrA promoters - Method 2

The protocol described above is one example of many by which one skilled in the art can derive an expression plasmid suitable for directing the synthesis of an *H. pylori* antigen, *e.g.*, urease, under the control of the *htrA* or *nirB* promoter in an attenuated strain of Salmonella. Alternative primers can be used in the PCR amplification of the genes from the starting plasmid, and alternative strategies for the introduction of the gene *via* alternative restriction sites are possible. One such alternative was employed in the construction of plasmids pNUR3 and pHUR3. During the design of the primers for PCR, a sequence error in the database-deposited gene sequence caused the 3' end of the *ureB* gene to be incorrectly identified. A primer was synthesized for the PCR amplification that, in fact, resulted in a non-native sequence of the gene, containing an additional 49 codons after the genuine termination codon. This error was subsequently corrected by the method described below, yielding a final plasmid with a sequence identical to that of the plasmid that would be produced by the strategy described above. This method is described in further detail, as follows.

As is described above, plasmid pORV273 was obtained from OraVax Inc. Plasmid ptetnir15 has been described (Chatfield *et al.*, Bio/Technology 10:888-892, 1992; Oxer *et al.*, Nucl. Acids Res. 19:1889-1892, 1991), and this vector was modified by standard techniques, to introduce into the vector a suitable restriction site for subcloning other genes for optimal expression under control of the *nirB* promoter. An *Nco*I site was introduced 10 basepairs 3' to the Shine-Dalgarno sequence of ptetnir15, and the resultant plasmid was designated ptetnir15/mod. Plasmid ptetnir15/mod, carried in strain BRD940, was obtained from the culture collection of Peptide Therapeutics Ltd., Cambridge, U.K.

The ureAB gene was amplified by PCR from pORV273 using Turbo Pfu polymerase (Stratagene), which has 3'-5' proof-reading activity and two primers, designated orafor and orarev. Primer orafor introduces *Eco*RI and *Bsp*HI sites immediately upstream of the initiating codon of the *ureA* gene. Primer orarev introduces a *Bam*HI and a *Pst*I site just before the correct 3' end of the *ureAB* gene. Subsequent digestion and cloning, as is described below, resulted in the deletion of the correct termination codon of *ureB*, with the result that transcription continued into the vector sequence until an in-frame stop codon was reached, adding 49 amino acids to the translated protein.

The PCR reaction included 0.1 μg pORV273 and 100 pmol each of primers orafor (5'-TAG GGA ATT CTC ATG AAA CTC ACC CCA AAA G-3' (SEQ ID NO:31)) and orarev (5'-TCT ACT GCA GGA TCC AAA ATG CTA AAG AGT TGC G-3' (SEQ ID NO:33)) per 100 μl reaction, and utilized 25 cycles, with an annealing temperature of 50°C. The resulting 2.4 kb PCR product was purified from a 1% agarose gel using a Qiaquick gel extraction kit (Qiagen). The PCR product was digested with *Bsp*HI + *Bam*HI, and purified with a Promega Wizard DNA clean-up kit. Plasmid ptetnir15/mod was digested with *Nco*I + *Bam*HI (the *Nco*I site is 10 basepairs 3' to the Shine-Dalgarno sequence of ptetnir15, and generates a cohesive end that is compatible with *Bsp*HI), and dephosphorylated using shrimp alkaline phosphatase. The largest fragment from the digestion of ptetnir15/mod was isolated from a 1% agarose gel using a Qiaquick gel extraction kit (Qiagen), and ligated to the digested PCR product using the Ligator Express Kit (Clontech). Ligations were transformed into electrocompetent *E. coli* TG1 cells (Stratagene).

Plasmids from ampicillin-resistant transformants were screened for the presence of the full length, 2.4 kb *ureAB* gene by restriction analysis. The *ureAB* gene from plasmid pORV273 has a *Bam*HI site within the coding sequence. However, in a small number of ptetnir15/mod + *ureAB* transformants, incomplete digestion or re-ligation of the two *ureAB* fragments yielded the full length *ureAB* PCR product. The orientation of the *ureAB* gene in the ptetnir15-derived plasmid was confirmed by PCR and a plasmid with the full length *ureAB* gene, in the correct orientation was designated pNUR1.

The *nirB* promoter in plasmid pNUR1 was replaced with the *htrA* promoter from phtrAcore, which is obtained from Peptide Therapeutics Ltd., Cambridge, U.K. Plasmids pNUR1 and phtrAcore were digested with *Pst*I and *Bgl*II. Digested pNUR1 was dephosphorylated with shrimp alkaline phosphatase. The digests were run on a 1% agarose gel, and a 0.8 kb fragment containing the *htrA* promoter from the phtrAcore digest and the 4.0 kb fragment from pNUR1 lacking the *nirB* promoter were extracted from the gel using a Qiagen Qiaquick gel extraction kit. The two fragments were ligated together (Clontech Ligator express kit) and transformed into electrocompetent *E. coli* TG1 cells (Stratagene). Transformants were screened for the presence of the *htrA* promoter by PCR using primer pairs specific for *htrA* (5902/5904) or *nirB* (5901/5904). A plasmid with the *htrA* promoter and a full length *ureAB* gene was designated pHUR1.

Subsequent to this it was discovered that there had been a cloning error in the 3' terminal portion of *ureB*, resulting in a translated product with an additional 49 amino acids from both pHUR1 and pNUR1. This was corrected by replacing the small *Bam*HI fragment containing the C-terminus of the *ureB* gene with the corresponding, and correct, fragment from pORV272. pORV273, pHUR1, and pNUR1 were digested with *Bam*HI,

and the small fragment from the pORV273 digestion was ligated to the large fragment from the pHUR1 and pNUR1 digestions. Clones were screened for orientation of the insert, and clones with the correct orientation were designated pHUR3 and pNUR3. These clones were characterized by full nucleotide sequencing of the region including the promoter and the complete *ureAB* gene on both strands, and found to be correct.

The nucleotide sequences across the *nirB* promoter and *ureAB* genes of pNUR1 and of the *htrA* promoter region of pHUR1 were confirmed. Samples of the two plasmids were prepared using the Qiagen "Plasmid midi kit" (Catalogue No. 12143), and the DNA sequence was determined by standard techniques known in the art. Oligonucleotides 5901 to 5919 were used, which allow nucleotide sequence determination of both DNA strands. Oligonucleotides 5901 and 5902 hybridize within *nirB* and *htrA*, respectively, while 5919 hybridizes within ptetnir15/mod downstream of the *ureAB* genes. The other oligonucleotides hybridize within the *ureAB* genes. These were diluted to 1 pmol μl^{-1}, packed in dry ice with the plasmid samples, and sent to Cambridge Bioscience (Cambridge) for nucleotide sequence determination. The data confirmed that the nucleotide sequence across the recombinant region of all three plasmids was as expected.

Sequences of primers that can be used in the invention, as is described above, are as follows.

5901
Primes within *nirB* promoter ~60 basepairs upstream of SD sequence
TCA AAT GGT ACC CCT TGC TGA (SEQ ID NO:34)

5902
Primes within *htrA* promoter ~60 basepairs upstream of SD sequence
TAT TCC GGA ACT TCG CGT TA (SEQ ID NO:35)

5903
Primes ~250 basepairs downstream from start of *ureA* gene
TGT TTC CTG ATG GGA CTA AAC TC (SEQ ID NO:36)

5904
Reverse primes ~300 basepairs downstream from start of *ureA* gene
ACC AGG AAC TAA TTT ACC ATT G (SEQ ID NO:37)

5905
Primes ~550 basepairs downstream from start of *ureA* gene
TTG ATT GAC ATT GGC GGT AAC (SEQ ID NO:38)

5906
Reverse primes ~600 basepairs from start of *ureA* gene
GTT GTC TGC TTG TCT ATC AAC C (SEQ ID NO:39)

5907
Primes ~150 basepairs downstream from start of *ureB* gene
GGT GGC GGT AAA ACC CTA AGA G (SEQ ID NO:40)

5908
Reverse primes ~180 basepairs downstream of *ureB* gene
CTT TGC TAG GGT TGT TAG ATT G (SEQ ID NO:41)

5909
Primes ~400 basepairs downstream from start of *ureB* gene
AAT CCC TAC AGC TTT TGC AAG C (SEQ ID NO:42)

5910
Reverse primes ~500 basepairs from start of *ureB* gene
GTG CCA TCA GCA GGA CCG GTT C (SEQ ID NO:43)

5911
Primes ~750 basepairs from start of *ureB* gene
ATC GCC ACA GAC ACT TTG AAT G (SEQ ID NO:44)

5912
Reverse primes ~820 basepairs downstream from start of *ureB* gene
TAG CAG CCA TAG TGT CTT CTA C (SEQ ID NO:45)

5913
Primes ~1050 basepairs downstream from start of *ureB* gene
TGA AGA CAC TTT GCA TGA CAT G (SEQ ID NO:46)

5914
Reverse primes 1080 basepairs downstream of *ureB* gene
TGA GAG TCA GAA CTG GTG ATT G (SEQ ID NO:47)

5915
Primes ~1350 basepairs downstream from start of *ureB* gene
CAT GAT CAT CAA AGG CGG ATT C (SEQ ID NO:48)

5916
Reverse primes ~1380 basepairs downstream from start of *ureB*
GAA GCG TTC GCA TCG CCC ATT TG (SEQ ID NO:49)

5917
Primes ~1650 basepairs from start of *ureB*
TCG TGG ATG GCA AAG AAG TAA C (SEQ ID NO:50)

5918
Reverse primes ~1680 basepairs from start of *ureB*
GCG CCA AGC TCA CTT TAT TG (SEQ ID NO:51)

5919
Reverse primes ~80 basepairs downstream of *Bam*HI site downstream of *ureB*
CAA CGA CAG GAG CAC GAT CAT G (SEQ ID NO:52)

The nucleotide sequences across the promoter regions and *ureAB* genes of the final plasmids, pHUR3 and pNUR3, were also confirmed. *E. coli* MC1061 cells containing the plasmids were sent to Cambridge Biosciences Ltd., who prepared plasmid DNA and determined the nucleotide sequences of the promoter and *ureAB* genes of both plasmids. The data confirmed that the nucleotide sequence across the relevant region of both plasmids was as expected. The sequence of plasmid pHUR3 is

shown in Fig. 4, and a plasmid map showing its relevant features is provided in Fig. 5.

Plasmids pNUR and pHUR were introduced into *S. typhimurium* strains BRD509 and BRD807, and *S. typhi* strains CVD908 and BRD948, by electroporation and selection of ampicillin-resistant colonies.

Immunization and Protection Experiments

Inbred Balb/C mice were immunized by the intragastric route with live, attenuated *Salmonella typhimurium* (1E10 CFU/ml) expressing urease apoenzyme on day 0 (Fig. 1). Animals were boosted twice on days 21 and 35 with 10 μg soluble, recombinant urease plus aluminum hydroxide (200 μg) by the parenteral route. Fourteen days later, serum antibody responses to urease were measured. Controls included: (1) prime-boost with the Salmonella parental control strains (BRD509 ΔaroA/ΔaroD (Strugnell *et al.*, Infection and Immunity 60:3994-4002, 1992) and BRD807ΔaroA/ΔhtrA (Chatfield *et al.*, Microbial Pathogenesis 12:145-151, 1992)) minus the urease construct, (2) mucosal priming with LT in place of Salmonella (gold standard), and (3) parenteral immunization with urease plus alum alone. Attenuated *S. typhimurium* (ΔaroA/ΔaroD) expressing urease under the transcriptional control of either an *htr*A promoter (pHUR3) or the *nir*B promoter (pNUR3) induced an elevated IgG2a response against urease that was greater than the gold standard using LT-Alum (Fig. 2A). A comparable response to LT-Alum was induced with *S. typhimurium* (ΔaroA/ΔhtrA) carrying the same urease constructs (Fig. 2A). Analysis of the IgG1/IgG2a ratio demonstrated the induction of a Th1 response with the double aro mutant, and a more balanced response with the Δaro/ΔhtrA mutant strain (Fig. 2B). Urease-specific antibody in Fig. 2A is expressed as EU/ml on a logarithmic scale and median response is indicated by the bar.

The level of protective efficacy employing *S. typhimurium*-vectored urease in a prime-boost strategy was determined. Fig. 3A shows the results of quantitative *H. pylori* culture of mice immunized on day 0 with 1E10 CFU/ml live attenuated *S. typhimurium* (ΔaroA/ΔaroD or ΔaroA/ΔhtrA) and boosted on days 21 and 35 with urease (10 μg) plus alum (200 μg). Three weeks later, animals were challenged with *H. pylori* (1E7 CFU/ml) and efficacy was assessed in gastric tissue 4 weeks later using quantitative culture. Strains including the urease constructs are indicated in the key of Fig. 3A. Fig. 3B shows protection depicted as $\log_{10}$ reduction in comparison to the no treatment (Tx) control group. A significant reduction in bacterial burden was observed when attenuated Salmonella expressing urease was administered as part of a prime-boost regimen with alum (Wilcoxon rank sum compared to parental control strain). No significant difference was observed between group 1 (pHUR3-Alum) and group 7 (LT-Alum).

All patents and publications cited above are hereby incorporated by reference in their entirety.

What is claimed is:

1. A method of inducing an immune response against Helicobacter in a mammal, said method comprising the steps of:

mucosally administering to said mammal an attenuated Salmonella vector comprising a nucleic acid molecule encoding a Helicobacter antigen, and

parenterally administering to said mammal a Helicobacter antigen.

2. The method of claim 1, wherein said attenuated Salmonella vector is administered orally to said mammal.

3. The method of claim 1, wherein said Helicobacter antigen is a urease, a urease subunit, or an immunogenic fragment thereof

4. The method of claim 1, wherein said mammal is at risk of developing, but does not have, a Helicobacter infection.

5. The method of claim 1, wherein said mammal has a Helicobacter infection.

6. The method of claim 1, wherein said parenteral administration of said Helicobacter antigen further includes parenteral administration of an adjuvant.

7. The method of claim 6, wherein said adjuvant is an aluminum compound.

8. The method of claim 7, wherein said aluminum compound is alum.

9. The method of claim 1, wherein said attenuated Salmonella vector is a *Salmonella typhi* vector.

10. The method of claim 9, wherein said *Salmonella typhi* vector is CVD908-htrA or CVD908.

11. The method of claim 1, wherein the attenuated Salmonella vector is a *Salmonella typhimurium* vector.

12. The method of claim 11, wherein said *Salmonella typhimurium* vector is BRD509 or BRD807.

13. The method of claim 1, wherein said attenuated Salmonella vector further comprises an *htrA* promoter.

14. The method of claim 1, wherein said attenuated Salmonella vector further comprises a *nirB* promoter.

15. The method of claim 1, wherein said mucosal administration primes an immune response to an antigen and said parenteral administration boosts an immune response to said antigen.

16. An attenuated Salmonella vector comprising a nucleic acid molecule encoding a Helicobacter antigen.

17. The vector of claim 16, wherein said antigen is a urease, a urease subunit, or an immunogenic fragment thereof.

18. The vector of claim 16, wherein said attenuated Salmonella vector is a *Salmonella typhi* vector.

19. The vector of claim 18, wherein said *Salmonella typhi* vector is CVD908-htrA or CVD908.

20. The vector of claim 16, wherein the attenuated Salmonella vector is a *Salmonella typhimurium* vector.

21. The vector of claim 20, wherein said *Salmonella typhimurium* vector is BRD509 or BRD807.

22. The vector of claim 16, wherein said attenuated Salmonella vector further comprises an *htrA* promoter.

23. The vector of claim 16, wherein said attenuated Salmonella vector further comprises a *nirB* promoter.



Fig. 1

Figure 2. Mucosal priming with *S. typhimurium* vectored urease followed by parenteral boosting with alum induces an IgG2a humural immune response equivalent to that induced by mucosal priming with LT.



Figure 3. Mucosal priming with attenuated *S. typhimurium::ureA/B* affords equivalent protection as LT in a prime-boost regimen with Alum

A



B

Group	Δ log10 CFU	*P-value*
S. typhimuriumΔaroA,aroD		
1. pHUR3-Alum	1.69	0.0002
2. pNUR3-Alum	1.45	0.003
3. BRD509-Alum	0.75	-
S. typhimuriumΔaroA,htrA		
4. pHUR3-Alum	1.31	0.004
5. pNUR3-Alum	1.29	0.006
6. BRD807-Alum	0.37	-
7. LT-Alum	2.15	<0.0001
8. Alum	0.33	0.01
9. No Tx	-	

Fig. 4 (1 of 4)

```
EcoR I                                                                                  Bgl II
GAATTCTATTCCGGAACTTCGCGTTATAAAATGAATCTGACGTACACAGCAATTTAGATATTAATCATCCACAGGAGAGATCTCCATGAA 90
                                  PhtrA                                                   Ure
 N  S  I  P  E  L  R  V  I  K  .  I  .  R  T  Q  Q  F  R  Y  .  S  S  T  G  E  I  S  M  K
ACTCACCCCAAAAGAGTTAGATAAGTTGATGCTCCACTACGCTGGAGAATTGGCTAAAAAACGCAAAGAAAAAGGCATTAAGCTTAACTA 180
                                   UreA
 L  T  P  K  E  L  D  K  L  M  L  H  Y  A  G  E  L  A  K  K  R  K  E  K  G  I  K  L  N  Y
TGTAGAAGCAGTAGCTTTGATTAGTGCCCATATTATGGAAGAAGCGAGAGCTGGTAAAAAGACTGCGGCTGAATTGATGCAAGAAGGGCG 270
                                   UreA
 V  E  A  V  A  L  I  S  A  H  I  M  E  E  A  R  A  G  K  K  T  A  A  E  L  M  Q  E  G  R
CACTCTTTTAAAACCAGATGATGTGATGGATGGCGTGGCAAGCATGATCCATGAAGTGGGTATTGAAGCGATGTTTCCTGATGGGACTAA 360
                                   UreA
 T  L  L  K  P  D  D  V  M  D  G  V  A  S  M  I  H  E  V  G  I  E  A  M  F  P  D  G  T  K
ACTCGTAACCGTGCATACCCCTATTGAGGCCAATGGTAAATTAGTTCCTGGTGAGTTGTTCTTAAAAAATGAAGACATCACTATCAACGA 450
                                   UreA
 L  V  T  V  H  T  P  I  E  A  N  G  K  L  V  P  G  E  L  F  L  K  N  E  D  I  T  I  N  E
AGGCAAAAAAGCCGTTAGCGTGAAAGTTAAAAATGTTGGCGACAGACCGGTTCAAATCGGCTCACACTTCCATTTCTTTGAAGTGAATAG 540
                                   UreA
 G  K  K  A  V  S  V  K  V  K  N  V  G  D  R  P  V  Q  I  G  S  H  F  H  F  F  E  V  N  R
ATGCCTAGACTTTGACAGAGAAAAAACTTTCGGTAAACGCTTAGACATTGCGAGCGGGACAGCGGTAAGATTTGAGCCTGGCGAAGAAAA 630
                                   UreA
 C  L  D  F  D  R  E  K  T  F  G  K  R  L  D  I  A  S  G  T  A  V  R  F  E  P  G  E  E  K
ATCCGTAGAATTGATTGACATTGGCGGTAACAGAAGAATCTTTGGATTTAACGCATTGGTTGATAGACAAGCAGACAACGAAAGCAAAAA 720
                                   UreA
 S  V  E  L  I  D  I  G  G  N  R  R  I  F  G  F  N  A  L  V  D  R  Q  A  D  N  E  S  K  K
AATTGCTTTACACAGAGCTAAAGAGCGTGGTTTTCATGGCGCTAAAAGCGATGACAACTATGTAAAAACAATTAAGGAGTAAGAAATGAA 810
                                 UreA                                                     Ure
 I  A  L  H  R  A  K  E  R  G  F  H  G  A  K  S  D  D  N  Y  V  K  T  I  K  E  .  E  M  K
AAAGATTAGCAGAAAAGAATATGTTTCTATGTATGGTCCTACTACAGGCGATAAAGTGAGATTGGGCGATACAGACTTGATCGCTGAAGT 900
                                   UreB
 K  I  S  R  K  E  Y  V  S  M  Y  G  P  T  T  G  D  K  V  R  L  G  D  T  D  L  I  A  E  V
AGAACATGACTACACCATTTATGGCGAAGAGCTTAAATTCGGTGGCGGTAAAACCCTAAGAGAAGGCATGAGCCAATCTAACAACCCTAG 990
                                   UreB
 E  H  D  Y  T  I  Y  G  E  E  L  K  F  G  G  G  K  T  L  R  E  G  M  S  Q  S  N  N  P  S
CAAAGAAGAGTTGGATTTAATTATCACTAACGCTTTAATCGTGGATTACACCGGTATTTATAAAGCGGATATTGGTATTAAAGATGGCAA 1080
                                   UreB
 K  E  E  L  D  L  I  I  T  N  A  L  I  V  D  Y  T  G  I  Y  K  A  D  I  G  I  K  D  G  K
AATCGCTGGCATTGGTAAAGGCGGTAACAAAGACATGCAAGATGGCGTTAAAAACAATCTTAGCGTAGGTCCTGCTACTGAAGCCTTAGC 1170
                                   UreB
 I  A  G  I  G  K  G  G  N  K  D  M  Q  D  G  V  K  N  N  L  S  V  G  P  A  T  E  A  L  A
CGGTGAAGGTTTGATCGTAACGGCTGGTGGTATTGACACACACATCCACTTCATTTCACCCCAACAAATCCCTACAGCTTTTGCAAGCGG 1260
                                   UreB
 G  E  G  L  I  V  T  A  G  G  I  D  T  H  I  H  F  I  S  P  Q  Q  I  P  T  A  F  A  S  G
```

Fig. 4 (2 of 4)

TGTAACAACCATGATTGGTGGTGGAACCGGTCCTGCTGATGGCACTAATGCGACTACTATCACTCCAGGCAGAAGAAATTTAAAATGGAT 1350

UreB

V T T M I G G G T G P A D G T N A T T I T P G R R N L K W M

GCTCAGAGCGGCTGAAGAATATTCTATGAATTTAGGTTTCTTGGCTAAAGGTAACGCTTCTAACGATGCGAGCTTAGCCGATCAAATTGA 1440

UreB

L R A A E E Y S M N L G F L A K G N A S N D A S L A D Q I E

AGCCGGTGCGATTGGCTTTGCAATTCACGAAGACTGGGGCACCACTCCTTCTGCAATCAATCATGCGTTAGATGTTGCGGACAAATACGA 1530

UreB

A G A I G F A I H E D W G T T P S A I N H A L D V A D K Y D

TGTGCAAGTCGCTATCGCCACAGACACTTTGAATGAAGCCGGTTGTGTAGAAGACACTATGGCTGCTATTGCTGGACGCACTATGCACAC 1620

UreB

V Q V A I A T D T L N E A G C V E D T M A A I A G R T M H T

TTTCCACACTGAAGGCGCTGGCGGCGGACACGCTCCTGATATTATTAAAGTAGCCGGTGAACACAACATTCTTCCCGCTTCCACTAACCC 1710

UreB

F H T E G A G G G H A P D I I K V A G E H N I L P A S T N P

CACCATCCCTTTCACCGTGAATACAGAAGCAGAGCACATGGACATGCTTATGGTGTGCCACCACTTGGATAAAAGCATTAAAGAAGATGT 1800

UreB

T I P F T V N T E A E H M D M L M V C H H L D K S I K E D V

Bam HI

TCAGTTCGCTGATTCAAGGATCCGCCCTCAAACCATTGCGGCTGAAGACACTTTGCATGACATGGGGATTTTCTCAATCACCAGTTCTGA 1890

UreB

Q F A D S R I R P Q T I A A E D T L H D M G I F S I T S S D

CTCTCAAGCGATGGGCCGTGTGGGTGAAGTTATCACTAGAACTTGGCAAACAGCTGACAAAAACAAGAAAGAATTTGGCCGCTTGAAAGA 1980

UreB

S Q A M G R V G E V I T R T W Q T A D K N K K E F G R L K E

AGAAAAAGGCGATAACGACAACTTCAGGATCAAACGCTACTTGTCTAAATACACCATTAACCCAGCGATCGCTCATGGGATTAGCGAGTA 2070

UreB

E K G D N D N F R I K R Y L S K Y T I N P A I A H G I S E Y

TGTAGGTTCAGTAGAAGTGGGCAAAGTGGCTGACTTGGTATTGTGGAGTCCAGCATTCTTTGGCGTGAAACCCAACATGATCATCAAAGG 2160

UreB

V G S V E V G K V A D L V L W S P A F F G V K P N M I I K G

CGGATTCATTGCGTTAAGCCAAATGGGCGATGCGAACGCTTCTATCCCTACCCCACAACCGGTTTATTACAGAGAAATGTTCGCTCATCA 2250

UreB

G F I A L S Q M G D A N A S I P T P Q P V Y Y R E M F A H H

TGGTAAAGCTAAATACGATGCAAACATCACTTTTGTGTCTCAAGCGGCTTATGACAAAGGCATTAAAGAAGAATTAGGACTTGAAAGACA 2340

UreB

G K A K Y D A N I T F V S Q A A Y D K G I K E E L G L E R Q

AGTGTTGCCGGTAAAAAATTGCAGAAATATCACTAAAAAAGACATGCAATTCAACGACACTACCGCTCACATTGAAGTCAATCCTGAAAC 2430

UreB

V L P V K N C R N I T K K D M Q F N D T T A H I E V N P E T

TTACCATGTGTTCGTGGATGGCAAAGAAGTAACTTCTAAACCAGCCAATAAAGTGAGCTTGGCGCAACTCTTTAGCATTTTCTAGGATTT 2520

UreB

Y H V F V D G K E V T S K P A N K V S L A Q L F S I F . D F

Bam HI

TTTAGGAGCAACGCTCCTTAGATCCCCGGGAATTGGGGATCCGCTAGCCCGCCTAATGAGCGGGCTTTTTTTTCTCGGGCAGCGTTGGGT 2610

L G A T L L R S P G I G D P L A R L M S G L F F L G Q R W V

Fig. 4 (3 of 4)

CCTGGCCACGGGTGCGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGGTTGCCTTACTGGTTAGCAGAATGAATCAC 2700

L A T G A H D R A P V V E D P A R L A G L P Y W L A E . I T

CGATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAAACGTCTGCGACCTGAGCAACAACATGAATGGTCTTCGGTTTCCGTGTTTCGT 2790

D T R A N V K R L L L Q N V C D L S N N M N G L R F P C F V

AAAGTCTGGAAACGCGGAAGTCAGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCA 2880

K S G N A E V S A L P L P R S L T R C A R S F G C G E R Y Q

GCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGG 2970

Origin

L T Q R R . Y G Y P Q N Q G I T Q E R T C E Q K A S K R P G

AACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGG 3060

Origin

T V K R P R C W R F S I G S A P L T S I T K I D A Q V R G G

CGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGA 3150

Origin

E T R Q D Y K D T R R F P L E A P S C A L L F R P C R L P D

TACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCC 3240

Origin

T C P P F S L R E A W R F L N A H A V G I S V R C R S F A P

AAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACAC 3330

Origin

S W A V C T N P P F S P T A A P Y P V T I V L S P T R . D T

GACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCT 3420

Origin

T Y R H W Q Q P L V T G L A E R G M . A V L Q S S . S G G L

AACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCC 3510

Origin

T T A T L E G Q Y L V S A L C . S Q L P S E K E L V A L D P

GGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTG 3600

Origin

A N K P P L V A V V F L F A S S R L R A E K K D L K K I L .

ATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAG 3690

S F L R G L T L S G T K T H V K G F W S . D Y Q K G S S P R

ATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAG 3780

AmpR

S F . I K N E V L N Q S K V Y M S K L G L T V T N A . S V R

GCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCA 3870

AmpR

H L S Q R S V Y F V H P . L P D S P S C R . L R Y G R A Y H

TCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAG 3960

AmpR

L A P V L Q . Y R E T H A H R L Q I Y Q Q . T S Q P E G P S

CGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGT 4050

AmpR

A E V V L Q L Y P P P S S L L I V A G K L E . V V R Q L I V

Fig. 4 (4 of 4)

Pst I

TTGCGCAACGTTGTTGCCATTGCTGCAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCA 4140

AmpR

C A T L L P L L Q A S W C H A R R L V W L H S A P V P N D Q

AGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTG 4230

AmpR

G E L H D P P C C A K K R L A P S V L R S L S E V S W P Q C

TTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACC 4320

AmpR

Y H S W L W Q H C I I L L L S C H P . D A F L . L V S T Q P

AAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTA 4410

AmpR

S H S E N S V C G D R V A L A R R Q H G I I P R H I A E L .

AAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGT 4500

AmpR

K C S S L E N V L R G E N S Q G S Y R C . D P V R C N P L V

GCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATA 4590

AmpR

H P T D L Q H L L L S P A F L G E Q K Q E G K M P Q K R E .

AGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATAC 4680

AmpR

G R H G N V E Y S Y S S F F N I I E A F I R V I V S . A D T

ATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTCTAAGAAACCATTATT 4770

Y L N V F R K I N K . G F R A H F P E K C H L T S K K P L L

ATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAA 4824

S . H . P I K I G V S R G P F V F K


EcoR I
Bgl II
Pst I
0.5 Kb
UreA
1.0 Kb
1.5 Kb
UreB
2.0 Kb
Bam HI
2.5 Kb
Bam HI
3.0 Kb
Origin
3.5 Kb
4.0 Kb
AmpR
4.5 Kb

Fig. 5

SEQUENCE LISTING

<110> OraVax, Inc.

<120> Use of salmonella vectors for
vaccination against helicobacter infection

<130> 06132/060WO1

<150> US 09/431,705
<151> 1999-11-01

<160> 52

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 4824
<212> DNA
<213> Artificial Sequence

<220>
<223> includes sequences from Helicobacter pylori,
Salmonella typhimurium, and Escherichia coli

<221> CDS
<222> (2)...(31)

<221> CDS
<222> (41)...(61)

<221> CDS
<222> (65)...(799)

<221> CDS
<222> (803)...(2512)

<221> CDS
<222> (2516)...(2692)

<221> CDS
<222> (2696)...(2896)

<221> CDS
<222> (2900)...(3322)

<221> CDS
<222> (3326)...(3385)

```
<221> CDS
<222> (3389)...(3406)

<221> CDS
<222> (3410)...(3466)

<221> CDS
<222> (3470)...(3598)

<221> CDS
<222> (3602)...(3661)

<221> CDS
<222> (3665)...(3697)

<221> CDS
<222> (3701)...(3769)

<221> CDS
<222> (3773)...(3817)

<221> CDS
<222> (3821)...(3844)

<221> CDS
<222> (3848)...(3889)

<400> 1
g aat tct att ccg gaa ctt cgc gtt ata aaa tgaatctga cgt aca cag    49
  Asn Ser Ile Pro Glu Leu Arg Val Ile Lys           Arg Thr Gln
   1               5                  10

caa ttt aga tat taa tca tcc aca gga gag atc tcc atg aaa ctc acc    97
Gln Phe Arg Tyr     Ser Ser Thr Gly Glu Ile Ser Met Lys Leu Thr
     15                      20                  25

cca aaa gag tta gat aag ttg atg ctc cac tac gct gga gaa ttg gct   145
Pro Lys Glu Leu Asp Lys Leu Met Leu His Tyr Ala Gly Glu Leu Ala
     30                  35                  40

aaa aaa cgc aaa gaa aaa ggc att aag ctt aac tat gta gaa gca gta   193
Lys Lys Arg Lys Glu Lys Gly Ile Lys Leu Asn Tyr Val Glu Ala Val
 45                  50                  55                  60

gct ttg att agt gcc cat att atg gaa gaa gcg aga gct ggt aaa aag   241
Ala Leu Ile Ser Ala His Ile Met Glu Glu Ala Arg Ala Gly Lys Lys
                 65                  70                  75

act gcg gct gaa ttg atg caa gaa ggg cgc act ctt tta aaa cca gat   289
Thr Ala Ala Glu Leu Met Gln Glu Gly Arg Thr Leu Leu Lys Pro Asp
             80                  85                  90
```

```
gat gtg atg gat ggc gtg gca agc atg atc cat gaa gtg ggt att gaa     337
Asp Val Met Asp Gly Val Ala Ser Met Ile His Glu Val Gly Ile Glu
         95                 100                 105

gcg atg ttt cct gat ggg act aaa ctc gta acc gtg cat acc cct att     385
Ala Met Phe Pro Asp Gly Thr Lys Leu Val Thr Val His Thr Pro Ile
    110                 115                 120

gag gcc aat ggt aaa tta gtt cct ggt gag ttg ttc tta aaa aat gaa     433
Glu Ala Asn Gly Lys Leu Val Pro Gly Glu Leu Phe Leu Lys Asn Glu
125                 130                 135                 140

gac atc act atc aac gaa ggc aaa aaa gcc gtt agc gtg aaa gtt aaa     481
Asp Ile Thr Ile Asn Glu Gly Lys Lys Ala Val Ser Val Lys Val Lys
                145                 150                 155

aat gtt ggc gac aga ccg gtt caa atc ggc tca cac ttc cat ttc ttt     529
Asn Val Gly Asp Arg Pro Val Gln Ile Gly Ser His Phe His Phe Phe
            160                 165                 170

gaa gtg aat aga tgc cta gac ttt gac aga gaa aaa act ttc ggt aaa     577
Glu Val Asn Arg Cys Leu Asp Phe Asp Arg Glu Lys Thr Phe Gly Lys
        175                 180                 185

cgc tta gac att gcg agc ggg aca gcg gta aga ttt gag cct ggc gaa     625
Arg Leu Asp Ile Ala Ser Gly Thr Ala Val Arg Phe Glu Pro Gly Glu
    190                 195                 200

gaa aaa tcc gta gaa ttg att gac att ggc ggt aac aga aga atc ttt     673
Glu Lys Ser Val Glu Leu Ile Asp Ile Gly Gly Asn Arg Arg Ile Phe
205                 210                 215                 220

gga ttt aac gca ttg gtt gat aga caa gca gac aac gaa agc aaa aaa     721
Gly Phe Asn Ala Leu Val Asp Arg Gln Ala Asp Asn Glu Ser Lys Lys
                225                 230                 235

att gct tta cac aga gct aaa gag cgt ggt ttt cat ggc gct aaa agc     769
Ile Ala Leu His Arg Ala Lys Glu Arg Gly Phe His Gly Ala Lys Ser
            240                 245                 250

gat gac aac tat gta aaa aca att aag gag taa gaa atg aaa aag att     817
Asp Asp Asn Tyr Val Lys Thr Ile Lys Glu     Glu Met Lys Lys Ile
        255                 260                     265

agc aga aaa gaa tat gtt tct atg tat ggt cct act aca ggc gat aaa     865
Ser Arg Lys Glu Tyr Val Ser Met Tyr Gly Pro Thr Thr Gly Asp Lys
        270                 275                 280

gtg aga ttg ggc gat aca gac ttg atc gct gaa gta gaa cat gac tac     913
Val Arg Leu Gly Asp Thr Asp Leu Ile Ala Glu Val Glu His Asp Tyr
```

```
    285                 290                 295

acc att tat ggc gaa gag ctt aaa ttc ggt ggc ggt aaa acc cta aga    961
Thr Ile Tyr Gly Glu Glu Leu Lys Phe Gly Gly Gly Lys Thr Leu Arg
300                 305                 310                 315

gaa ggc atg agc caa tct aac aac cct agc aaa gaa gag ttg gat tta    1009
Glu Gly Met Ser Gln Ser Asn Asn Pro Ser Lys Glu Glu Leu Asp Leu
                320                 325                 330

att atc act aac gct tta atc gtg gat tac acc ggt att tat aaa gcg    1057
Ile Ile Thr Asn Ala Leu Ile Val Asp Tyr Thr Gly Ile Tyr Lys Ala
            335                 340                 345

gat att ggt att aaa gat ggc aaa atc gct ggc att ggt aaa ggc ggt    1105
Asp Ile Gly Ile Lys Asp Gly Lys Ile Ala Gly Ile Gly Lys Gly Gly
        350                 355                 360

aac aaa gac atg caa gat ggc gtt aaa aac aat ctt agc gta ggt cct    1153
Asn Lys Asp Met Gln Asp Gly Val Lys Asn Asn Leu Ser Val Gly Pro
    365                 370                 375

gct act gaa gcc tta gcc ggt gaa ggt ttg atc gta acg gct ggt ggt    1201
Ala Thr Glu Ala Leu Ala Gly Glu Gly Leu Ile Val Thr Ala Gly Gly
380                 385                 390                 395

att gac aca cac atc cac ttc att tca ccc caa caa atc cct aca gct    1249
Ile Asp Thr His Ile His Phe Ile Ser Pro Gln Gln Ile Pro Thr Ala
                400                 405                 410

ttt gca agc ggt gta aca acc atg att ggt ggt gga acc ggt cct gct    1297
Phe Ala Ser Gly Val Thr Thr Met Ile Gly Gly Gly Thr Gly Pro Ala
            415                 420                 425

gat ggc act aat gcg act act atc act cca ggc aga aga aat tta aaa    1345
Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly Arg Arg Asn Leu Lys
        430                 435                 440

tgg atg ctc aga gcg gct gaa gaa tat tct atg aat tta ggt ttc ttg    1393
Trp Met Leu Arg Ala Ala Glu Glu Tyr Ser Met Asn Leu Gly Phe Leu
    445                 450                 455

gct aaa ggt aac gct tct aac gat gcg agc tta gcc gat caa att gaa    1441
Ala Lys Gly Asn Ala Ser Asn Asp Ala Ser Leu Ala Asp Gln Ile Glu
460                 465                 470                 475

gcc ggt gcg att ggc ttt gca att cac gaa gac tgg ggc acc act cct    1489
Ala Gly Ala Ile Gly Phe Ala Ile His Glu Asp Trp Gly Thr Thr Pro
                480                 485                 490

tct gca atc aat cat gcg tta gat gtt gcg gac aaa tac gat gtg caa    1537
```

```
Ser Ala Ile Asn His Ala Leu Asp Val Ala Asp Lys Tyr Asp Val Gln
            495                 500                 505

gtc gct atc gcc aca gac act ttg aat gaa gcc ggt tgt gta gaa gac     1585
Val Ala Ile Ala Thr Asp Thr Leu Asn Glu Ala Gly Cys Val Glu Asp
        510                 515                 520

act atg gct gct att gct gga cgc act atg cac act ttc cac act gaa     1633
Thr Met Ala Ala Ile Ala Gly Arg Thr Met His Thr Phe His Thr Glu
    525                 530                 535

ggc gct ggc ggc gga cac gct cct gat att att aaa gta gcc ggt gaa     1681
Gly Ala Gly Gly Gly His Ala Pro Asp Ile Ile Lys Val Ala Gly Glu
540                 545                 550                 555

cac aac att ctt ccc gct tcc act aac ccc acc atc cct ttc acc gtg     1729
His Asn Ile Leu Pro Ala Ser Thr Asn Pro Thr Ile Pro Phe Thr Val
                560                 565                 570

aat aca gaa gca gag cac atg gac atg ctt atg gtg tgc cac cac ttg     1777
Asn Thr Glu Ala Glu His Met Asp Met Leu Met Val Cys His His Leu
            575                 580                 585

gat aaa agc att aaa gaa gat gtt cag ttc gct gat tca agg atc cgc     1825
Asp Lys Ser Ile Lys Glu Asp Val Gln Phe Ala Asp Ser Arg Ile Arg
        590                 595                 600

cct caa acc att gcg gct gaa gac act ttg cat gac atg ggg att ttc     1873
Pro Gln Thr Ile Ala Ala Glu Asp Thr Leu His Asp Met Gly Ile Phe
    605                 610                 615

tca atc acc agt tct gac tct caa gcg atg ggc cgt gtg ggt gaa gtt     1921
Ser Ile Thr Ser Ser Asp Ser Gln Ala Met Gly Arg Val Gly Glu Val
620                 625                 630                 635

atc act aga act tgg caa aca gct gac aaa aac aag aaa gaa ttt ggc     1969
Ile Thr Arg Thr Trp Gln Thr Ala Asp Lys Asn Lys Lys Glu Phe Gly
                640                 645                 650

cgc ttg aaa gaa gaa aaa ggc gat aac gac aac ttc agg atc aaa cgc     2017
Arg Leu Lys Glu Glu Lys Gly Asp Asn Asp Asn Phe Arg Ile Lys Arg
            655                 660                 665

tac ttg tct aaa tac acc att aac cca gcg atc gct cat ggg att agc     2065
Tyr Leu Ser Lys Tyr Thr Ile Asn Pro Ala Ile Ala His Gly Ile Ser
        670                 675                 680

gag tat gta ggt tca gta gaa gtg ggc aaa gtg gct gac ttg gta ttg     2113
Glu Tyr Val Gly Ser Val Glu Val Gly Lys Val Ala Asp Leu Val Leu
    685                 690                 695
```

```
tgg agt cca gca ttc ttt ggc gtg aaa ccc aac atg atc atc aaa ggc     2161
Trp Ser Pro Ala Phe Phe Gly Val Lys Pro Asn Met Ile Ile Lys Gly
700                 705                 710                 715

gga ttc att gcg tta agc caa atg ggc gat gcg aac gct tct atc cct     2209
Gly Phe Ile Ala Leu Ser Gln Met Gly Asp Ala Asn Ala Ser Ile Pro
                720                 725                 730

acc cca caa ccg gtt tat tac aga gaa atg ttc gct cat cat ggt aaa     2257
Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe Ala His His Gly Lys
            735                 740                 745

gct aaa tac gat gca aac atc act ttt gtg tct caa gcg gct tat gac     2305
Ala Lys Tyr Asp Ala Asn Ile Thr Phe Val Ser Gln Ala Ala Tyr Asp
        750                 755                 760

aaa ggc att aaa gaa gaa tta gga ctt gaa aga caa gtg ttg ccg gta     2353
Lys Gly Ile Lys Glu Glu Leu Gly Leu Glu Arg Gln Val Leu Pro Val
    765                 770                 775

aaa aat tgc aga aat atc act aaa aaa gac atg caa ttc aac gac act     2401
Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Met Gln Phe Asn Asp Thr
780                 785                 790                 795

acc gct cac att gaa gtc aat cct gaa act tac cat gtg ttc gtg gat     2449
Thr Ala His Ile Glu Val Asn Pro Glu Thr Tyr His Val Phe Val Asp
                800                 805                 810

ggc aaa gaa gta act tct aaa cca gcc aat aaa gtg agc ttg gcg caa     2497
Gly Lys Glu Val Thr Ser Lys Pro Ala Asn Lys Val Ser Leu Ala Gln
            815                 820                 825

ctc ttt agc att ttc tag gat ttt tta gga gca acg ctc ctt aga tcc     2545
Leu Phe Ser Ile Phe     Asp Phe Leu Gly Ala Thr Leu Leu Arg Ser
        830                     835                 840

ccg gga att ggg gat ccg cta gcc cgc cta atg agc ggg ctt ttt ttt     2593
Pro Gly Ile Gly Asp Pro Leu Ala Arg Leu Met Ser Gly Leu Phe Phe
        845                 850                 855

ctc ggg cag cgt tgg gtc ctg gcc acg ggt gcg cat gat cgt gct cct     2641
Leu Gly Gln Arg Trp Val Leu Ala Thr Gly Ala His Asp Arg Ala Pro
    860                 865                 870

gtc gtt gag gac ccg gct agg ctg gcg ggg ttg cct tac tgg tta gca     2689
Val Val Glu Asp Pro Ala Arg Leu Ala Gly Leu Pro Tyr Trp Leu Ala
875                 880                 885                 890

gaa tga atc acc gat acg cga gcg aac gtg aag cga ctg ctg ctg caa     2737
Glu     Ile Thr Asp Thr Arg Ala Asn Val Lys Arg Leu Leu Leu Gln
                895                 900                 905
```

```
aac gtc tgc gac ctg agc aac aac atg aat ggt ctt cgg ttt ccg tgt    2785
Asn Val Cys Asp Leu Ser Asn Asn Met Asn Gly Leu Arg Phe Pro Cys
                910                 915                 920

ttc gta aag tct gga aac gcg gaa gtc agc gct ctt ccg ctt cct cgc    2833
Phe Val Lys Ser Gly Asn Ala Glu Val Ser Ala Leu Pro Leu Pro Arg
            925                 930                 935

tca ctg act cgc tgc gct cgg tcg ttc ggc tgc ggc gag cgg tat cag    2881
Ser Leu Thr Arg Cys Ala Arg Ser Phe Gly Cys Gly Glu Arg Tyr Gln
        940                 945                 950

ctc act caa agg cgg taa tac ggt tat cca cag aat cag ggg ata acg    2929
Leu Thr Gln Arg Arg     Tyr Gly Tyr Pro Gln Asn Gln Gly Ile Thr
    955                     960                 965

cag gaa aga aca tgt gag caa aag gcc agc aaa agg cca gga acc gta    2977
Gln Glu Arg Thr Cys Glu Gln Lys Ala Ser Lys Arg Pro Gly Thr Val
    970                 975                 980

aaa agg ccg cgt tgc tgg cgt ttt tcc ata ggc tcc gcc ccc ctg acg    3025
Lys Arg Pro Arg Cys Trp Arg Phe Ser Ile Gly Ser Ala Pro Leu Thr
985                 990                 995                     1000

agc atc aca aaa atc gac gct caa gtc aga ggt ggc gaa acc cga cag    3073
Ser Ile Thr Lys Ile Asp Ala Gln Val Arg Gly Gly Glu Thr Arg Gln
                1005                1010                1015

gac tat aaa gat acc agg cgt ttc ccc ctg gaa gct ccc tcg tgc gct    3121
Asp Tyr Lys Asp Thr Arg Arg Phe Pro Leu Glu Ala Pro Ser Cys Ala
            1020                1025                1030

ctc ctg ttc cga ccc tgc cgc tta ccg gat acc tgt ccg cct ttc tcc    3169
Leu Leu Phe Arg Pro Cys Arg Leu Pro Asp Thr Cys Pro Pro Phe Ser
        1035                1040                1045

ctt cgg gaa gcg tgg cgc ttt ctc aat gct cac gct gta ggt atc tca    3217
Leu Arg Glu Ala Trp Arg Phe Leu Asn Ala His Ala Val Gly Ile Ser
    1050                1055                1060

gtt cgg tgt agg tcg ttc gct cca agc tgg gct gtg tgc acg aac ccc    3265
Val Arg Cys Arg Ser Phe Ala Pro Ser Trp Ala Val Cys Thr Asn Pro
1065                1070                1075                1080

ccg ttc agc ccg acc gct gcg cct tat ccg gta act atc gtc ttg agt    3313
Pro Phe Ser Pro Thr Ala Ala Pro Tyr Pro Val Thr Ile Val Leu Ser
                1085                1090                1095

cca acc cgg taa gac acg act tat cgc cac tgg cag cag cca ctg gta    3361
Pro Thr Arg     Asp Thr Thr Tyr Arg His Trp Gln Gln Pro Leu Val
```

```
        1100                1105                1110

aca gga tta gca gag cga ggt atg tag gcg gtg cta cag agt tct      3406
Thr Gly Leu Ala Glu Arg Gly Met     Ala Val Leu Gln Ser Ser
            1115                1120                1125

tga agt ggt ggc cta act acg gct aca cta gaa gga cag tat ttg gta  3454
    Ser Gly Gly Leu Thr Thr Ala Thr Leu Glu Gly Gln Tyr Leu Val
                1130                1135                1140

tct gcg ctc tgc tga agc cag tta cct tcg gaa aaa gag ttg gta gct  3502
Ser Ala Leu Cys     Ser Gln Leu Pro Ser Glu Lys Glu Leu Val Ala
                1145                1150                1155

ctt gat ccg gca aac aaa cca ccg ctg gta gcg gtg gtt ttt ttg ttt  3550
Leu Asp Pro Ala Asn Lys Pro Pro Leu Val Ala Val Val Phe Leu Phe
            1160                1165                1170

gca agc agc aga tta cgc gca gaa aaa aag gat ctc aag aag atc ctt  3598
Ala Ser Ser Arg Leu Arg Ala Glu Lys Lys Asp Leu Lys Lys Ile Leu
            1175                1180                1185

tga tct ttt cta cgg ggt ctg acg ctc agt gga acg aaa act cac gtt  3646
    Ser Phe Leu Arg Gly Leu Thr Leu Ser Gly Thr Lys Thr His Val
            1190                1195                1200

aag gga ttt tgg tca tga gat tat caa aaa gga tct tca cct aga tcc  3694
Lys Gly Phe Trp Ser     Asp Tyr Gln Lys Gly Ser Ser Pro Arg Ser
        1205                1210                1215

ttt taa att aaa aat gaa gtt tta aat caa tct aaa gta tat atg agt  3742
Phe     Ile Lys Asn Glu Val Leu Asn Gln Ser Lys Val Tyr Met Ser
            1220                1225                1230

aaa ctt ggt ctg aca gtt acc aat gct taa tca gtg agg cac cta tct  3790
Lys Leu Gly Leu Thr Val Thr Asn Ala     Ser Val Arg His Leu Ser
        1235                1240                1245

cag cga tct gtc tat ttc gtt cat cca tag ttg cct gac tcc ccg tcg  3838
Gln Arg Ser Val Tyr Phe Val His Pro     Leu Pro Asp Ser Pro Ser
        1250                1255                1260

tgt aga taa cta cga tac ggg agg gct tac cat ctg gcc cca gtg ctg  3886
Cys Arg     Leu Arg Tyr Gly Arg Ala Tyr His Leu Ala Pro Val Leu
            1265                1270                1275

caa tgataccgcg agacccacgc tcaccggctc cagatttatc agcaataaac       3939
Gln

cagccagccg gaagggccga gcgcagaagt ggtcctgcaa ctttatccgc ctccatccag 3999
```

```
tctattaatt gttgccggga agctagagta agtagttcgc cagttaatag tttgcgcaac 4059
gttgttgcca ttgctgcagg catcgtggtg tcacgctcgt cgtttggtat ggcttcattc 4119
agctccggtt cccaacgatc aaggcgagtt acatgatccc ccatgttgtg caaaaaagcg 4179
gttagctcct tcggtcctcc gatcgttgtc agaagtaagt tggccgcagt gttatcactc 4239
atggttatgg cagcactgca taattctctt actgtcatgc catccgtaag atgcttttct 4299
gtgactggtg agtactcaac caagtcattc tgagaatagt gtatgcggcg accgagttgc 4359
tcttgcccgg cgtcaacacg ggataatacc gcgccacata gcagaacttt aaaagtgctc 4419
atcattggaa aacgttcttc ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc 4479
agttcgatgt aacccactcg tgcacccaac tgatcttcag catcttttac tttcaccagc 4539
gtttctgggt gagcaaaaac aggaaggcaa aatgccgcaa aaaagggaat aagggcgaca 4599
cggaaatgtt gaatactcat actcttcctt tttcaatatt attgaagcat ttatcagggt 4659
tattgtctca tgagcggata catatttgaa tgtatttaga aaaataaaca aataggggtt 4719
ccgcgcacat ttccccgaaa agtgccacct gacgtctaag aaaccattat tatcatgaca 4779
ttaacctata aaaataggcg tatcacgagg ccctttcgtc ttcaa                 4824
```

<210> 2
<211> 10
<212> PRT
<213> Salmonella typhimurium

<400> 2

```
Asn Ser Ile Pro Glu Leu Arg Val Ile Lys
 1               5                  10
```

<210> 3
<211> 7
<212> PRT
<213> Salmonella typhimurium

<400> 3

```
Arg Thr Gln Gln Phe Arg Tyr
 1               5
```

<210> 4
<211> 245
<212> PRT
<213> Artificial Sequence

<220>
<223> includes sequences from Salmonella typhimurium and Helicobacter pylori.

<400> 4

```
Ser Ser Thr Gly Glu Ile Ser Met Lys Leu Thr Pro Lys Glu Leu Asp
 1               5                  10                  15
Lys Leu Met Leu His Tyr Ala Gly Glu Leu Ala Lys Lys Arg Lys Glu
            20                  25                  30
Lys Gly Ile Lys Leu Asn Tyr Val Glu Ala Val Ala Leu Ile Ser Ala
        35                  40                  45
```

His Ile Met Glu Glu Ala Arg Ala Gly Lys Lys Thr Ala Ala Glu Leu
50 55 60
Met Gln Glu Gly Arg Thr Leu Leu Lys Pro Asp Asp Val Met Asp Gly
65 70 75 80
Val Ala Ser Met Ile His Glu Val Gly Ile Glu Ala Met Phe Pro Asp
85 90 95
Gly Thr Lys Leu Val Thr Val His Thr Pro Ile Glu Ala Asn Gly Lys
100 105 110
Leu Val Pro Gly Glu Leu Phe Leu Lys Asn Glu Asp Ile Thr Ile Asn
115 120 125
Glu Gly Lys Lys Ala Val Ser Val Lys Val Lys Asn Val Gly Asp Arg
130 135 140
Pro Val Gln Ile Gly Ser His Phe His Phe Phe Glu Val Asn Arg Cys
145 150 155 160
Leu Asp Phe Asp Arg Glu Lys Thr Phe Gly Lys Arg Leu Asp Ile Ala
165 170 175
Ser Gly Thr Ala Val Arg Phe Glu Pro Gly Glu Glu Lys Ser Val Glu
180 185 190
Leu Ile Asp Ile Gly Gly Asn Arg Arg Ile Phe Gly Phe Asn Ala Leu
195 200 205
Val Asp Arg Gln Ala Asp Asn Glu Ser Lys Lys Ile Ala Leu His Arg
210 215 220
Ala Lys Glu Arg Gly Phe His Gly Ala Lys Ser Asp Asp Asn Tyr Val
225 230 235 240
Lys Thr Ile Lys Glu
245

<210> 5
<211> 570
<212> PRT
<213> Helicobacter pylori

<400> 5
Glu Met Lys Lys Ile Ser Arg Lys Glu Tyr Val Ser Met Tyr Gly Pro
1 5 10 15
Thr Thr Gly Asp Lys Val Arg Leu Gly Asp Thr Asp Leu Ile Ala Glu
20 25 30
Val Glu His Asp Tyr Thr Ile Tyr Gly Glu Glu Leu Lys Phe Gly Gly
35 40 45
Gly Lys Thr Leu Arg Glu Gly Met Ser Gln Ser Asn Asn Pro Ser Lys
50 55 60
Glu Glu Leu Asp Leu Ile Ile Thr Asn Ala Leu Ile Val Asp Tyr Thr
65 70 75 80
Gly Ile Tyr Lys Ala Asp Ile Gly Ile Lys Asp Gly Lys Ile Ala Gly
85 90 95
Ile Gly Lys Gly Gly Asn Lys Asp Met Gln Asp Gly Val Lys Asn Asn
100 105 110
Leu Ser Val Gly Pro Ala Thr Glu Ala Leu Ala Gly Glu Gly Leu Ile
115 120 125
Val Thr Ala Gly Gly Ile Asp Thr His Ile His Phe Ile Ser Pro Gln

130 135 140
Gln Ile Pro Thr Ala Phe Ala Ser Gly Val Thr Thr Met Ile Gly Gly
145 150 155 160
Gly Thr Gly Pro Ala Asp Gly Thr Asn Ala Thr Thr Ile Thr Pro Gly
165 170 175
Arg Arg Asn Leu Lys Trp Met Leu Arg Ala Ala Glu Glu Tyr Ser Met
180 185 190
Asn Leu Gly Phe Leu Ala Lys Gly Asn Ala Ser Asn Asp Ala Ser Leu
195 200 205
Ala Asp Gln Ile Glu Ala Gly Ala Ile Gly Phe Ala Ile His Glu Asp
210 215 220
Trp Gly Thr Thr Pro Ser Ala Ile Asn His Ala Leu Asp Val Ala Asp
225 230 235 240
Lys Tyr Asp Val Gln Val Ala Ile Ala Thr Asp Thr Leu Asn Glu Ala
245 250 255
Gly Cys Val Glu Asp Thr Met Ala Ala Ile Ala Gly Arg Thr Met His
260 265 270
Thr Phe His Thr Glu Gly Ala Gly Gly Gly His Ala Pro Asp Ile Ile
275 280 285
Lys Val Ala Gly Glu His Asn Ile Leu Pro Ala Ser Thr Asn Pro Thr
290 295 300
Ile Pro Phe Thr Val Asn Thr Glu Ala Glu His Met Asp Met Leu Met
305 310 315 320
Val Cys His His Leu Asp Lys Ser Ile Lys Glu Asp Val Gln Phe Ala
325 330 335
Asp Ser Arg Ile Arg Pro Gln Thr Ile Ala Ala Glu Asp Thr Leu His
340 345 350
Asp Met Gly Ile Phe Ser Ile Thr Ser Ser Asp Ser Gln Ala Met Gly
355 360 365
Arg Val Gly Glu Val Ile Thr Arg Thr Trp Gln Thr Ala Asp Lys Asn
370 375 380
Lys Lys Glu Phe Gly Arg Leu Lys Glu Glu Lys Gly Asp Asn Asp Asn
385 390 395 400
Phe Arg Ile Lys Arg Tyr Leu Ser Lys Tyr Thr Ile Asn Pro Ala Ile
405 410 415
Ala His Gly Ile Ser Glu Tyr Val Gly Ser Val Glu Val Gly Lys Val
420 425 430
Ala Asp Leu Val Leu Trp Ser Pro Ala Phe Phe Gly Val Lys Pro Asn
435 440 445
Met Ile Ile Lys Gly Gly Phe Ile Ala Leu Ser Gln Met Gly Asp Ala
450 455 460
Asn Ala Ser Ile Pro Thr Pro Gln Pro Val Tyr Tyr Arg Glu Met Phe
465 470 475 480
Ala His His Gly Lys Ala Lys Tyr Asp Ala Asn Ile Thr Phe Val Ser
485 490 495
Gln Ala Ala Tyr Asp Lys Gly Ile Lys Glu Glu Leu Gly Leu Glu Arg
500 505 510
Gln Val Leu Pro Val Lys Asn Cys Arg Asn Ile Thr Lys Lys Asp Met
515 520 525
Gln Phe Asn Asp Thr Thr Ala His Ile Glu Val Asn Pro Glu Thr Tyr
530 535 540

His Val Phe Val Asp Gly Lys Glu Val Thr Ser Lys Pro Ala Asn Lys
545 550 555 560
Val Ser Leu Ala Gln Leu Phe Ser Ile Phe
565 570

<210> 6
<211> 59
<212> PRT
<213> Salmonella typhimurium

<400> 6
Asp Phe Leu Gly Ala Thr Leu Leu Arg Ser Pro Gly Ile Gly Asp Pro
1 5 10 15
Leu Ala Arg Leu Met Ser Gly Leu Phe Phe Leu Gly Gln Arg Trp Val
20 25 30
Leu Ala Thr Gly Ala His Asp Arg Ala Pro Val Val Glu Asp Pro Ala
35 40 45
Arg Leu Ala Gly Leu Pro Tyr Trp Leu Ala Glu
50 55

<210> 7
<211> 67
<212> PRT
<213> Salmonella typhimurium

<400> 7
Ile Thr Asp Thr Arg Ala Asn Val Lys Arg Leu Leu Leu Gln Asn Val
1 5 10 15
Cys Asp Leu Ser Asn Asn Met Asn Gly Leu Arg Phe Pro Cys Phe Val
20 25 30
Lys Ser Gly Asn Ala Glu Val Ser Ala Leu Pro Leu Pro Arg Ser Leu
35 40 45
Thr Arg Cys Ala Arg Ser Phe Gly Cys Gly Glu Arg Tyr Gln Leu Thr
50 55 60
Gln Arg Arg
65

<210> 8
<211> 141
<212> PRT
<213> Salmonella typhimurium

<400> 8
Tyr Gly Tyr Pro Gln Asn Gln Gly Ile Thr Gln Glu Arg Thr Cys Glu
1 5 10 15
Gln Lys Ala Ser Lys Arg Pro Gly Thr Val Lys Arg Pro Arg Cys Trp
20 25 30
Arg Phe Ser Ile Gly Ser Ala Pro Leu Thr Ser Ile Thr Lys Ile Asp

```
        35                      40                      45
Ala Gln Val Arg Gly Gly Glu Thr Arg Gln Asp Tyr Lys Asp Thr Arg
    50                  55                  60
Arg Phe Pro Leu Glu Ala Pro Ser Cys Ala Leu Leu Phe Arg Pro Cys
65                  70                  75                  80
Arg Leu Pro Asp Thr Cys Pro Pro Phe Ser Leu Arg Glu Ala Trp Arg
                85                  90                  95
Phe Leu Asn Ala His Ala Val Gly Ile Ser Val Arg Cys Arg Ser Phe
            100                 105                 110
Ala Pro Ser Trp Ala Val Cys Thr Asn Pro Pro Phe Ser Pro Thr Ala
        115                 120                 125
Ala Pro Tyr Pro Val Thr Ile Val Leu Ser Pro Thr Arg
    130                 135                 140
```

<210> 9
<211> 20
<212> PRT
<213> Salmonella typhimurium

<400> 9

```
Asp Thr Thr Tyr Arg His Trp Gln Gln Pro Leu Val Thr Gly Leu Ala
 1               5                  10                  15
Glu Arg Gly Met
            20
```

<210> 10
<211> 6
<212> PRT
<213> Salmonella typhimurium

<400> 10

```
Ala Val Leu Gln Ser Ser
 1               5
```

<210> 11
<211> 19
<212> PRT
<213> Salmonella typhimurium

<400> 11

```
Ser Gly Gly Leu Thr Thr Ala Thr Leu Glu Gly Gln Tyr Leu Val Ser
 1               5                  10                  15
Ala Leu Cys
```

<210> 12
<211> 43

<212> PRT
<213> Salmonella typhimurium

<400> 12
Ser Gln Leu Pro Ser Glu Lys Glu Leu Val Ala Leu Asp Pro Ala Asn
1 5 10 15
Lys Pro Pro Leu Val Ala Val Val Phe Leu Phe Ala Ser Ser Arg Leu
20 25 30
Arg Ala Glu Lys Lys Asp Leu Lys Lys Ile Leu
35 40

<210> 13
<211> 20
<212> PRT
<213> Salmonella typhimurium

<400> 13
Ser Phe Leu Arg Gly Leu Thr Leu Ser Gly Thr Lys Thr His Val Lys
1 5 10 15
Gly Phe Trp Ser
20

<210> 14
<211> 11
<212> PRT
<213> Salmonella typhimurium

<400> 14
Asp Tyr Gln Lys Gly Ser Ser Pro Arg Ser Phe
1 5 10

<210> 15
<211> 23
<212> PRT
<213> Salmonella typhimurium

<400> 15
Ile Lys Asn Glu Val Leu Asn Gln Ser Lys Val Tyr Met Ser Lys Leu
1 5 10 15
Gly Leu Thr Val Thr Asn Ala
20

<210> 16
<211> 15
<212> PRT
<213> Salmonella typhimurium

<400> 16
Ser Val Arg His Leu Ser Gln Arg Ser Val Tyr Phe Val His Pro
1 5 10 15

<210> 17
<211> 8
<212> PRT
<213> Salmonella typhimurium

<400> 17
Leu Pro Asp Ser Pro Ser Cys Arg
1 5

<210> 18
<211> 14
<212> PRT
<213> Escherichia coli

<400> 18
Leu Arg Tyr Gly Arg Ala Tyr His Leu Ala Pro Val Leu Gln
1 5 10

<210> 19
<211> 4824
<212> DNA
<213> Artificial Sequence

<220>
<223> includes sequences from Helicobacter pylori,
Salmonella typhimurium, and Escherichia coli

<221> CDS
<222> (3893)...(3934)

<221> CDS
<222> (3938)...(4027)

<221> CDS
<222> (4031)...(4285)

<221> CDS
<222> (4289)...(4300)

<221> CDS
<222> (4304)...(4408)

<221> CDS
<222> (4412)...(4471)

<221> CDS
<222> (4475)...(4588)

<221> CDS
<222> (4592)...(4669)

<221> CDS
<222> (4673)...(4711)

<221> CDS
<222> (4715)...(4774)

<221> CDS
<222> (4784)...(4824)

<400> 19
gaattctatt ccggaacttc gcgttataaa atgaatctga cgtacacagc aatttagata 60
ttaatcatcc acaggagaga tctccatgaa actcacccca aaagagttag ataagttgat 120
gctccactac gctggagaat tggctaaaaa acgcaaagaa aaaggcatta agcttaacta 180
tgtagaagca gtagctttga ttagtgccca tattatggaa gaagcgagag ctggtaaaaa 240
gactgcggct gaattgatgc aagaagggcg cactctttta aaaccagatg atgtgatgga 300
tggcgtggca agcatgatcc atgaagtggg tattgaagcg atgtttcctg atgggactaa 360
actcgtaacc gtgcataccc ctattgaggc caatggtaaa ttagttcctg gtgagttgtt 420
cttaaaaaat gaagacatca ctatcaacga aggcaaaaaa gccgttagcg tgaaagttaa 480
aaatgttggc gacagaccgg ttcaaatcgg ctcacacttc catttctttg aagtgaatag 540
atgcctagac tttgacagag aaaaaacttt cggtaaacgc ttagacattg cgagcgggac 600
agcggtaaga tttgagcctg gcgaagaaaa atccgtagaa ttgattgaca ttggcggtaa 660
cagaagaatc tttggattta acgcattggt tgatagacaa gcagacaacg aaagcaaaaa 720
aattgcttta cacagagcta aagagcgtgg ttttcatggc gctaaaagcg atgacaacta 780
tgtaaaaaca attaaggagt aagaaatgaa aaagattagc agaaaagaat atgtttctat 840
gtatggtcct actacaggcg ataaagtgag attgggcgat acagacttga tcgctgaagt 900
agaacatgac tacaccattt atggcgaaga gcttaaattc ggtggcggta aaaccctaag 960
agaaggcatg agccaatcta acaaccctag caaagaagag ttggatttaa ttatcactaa 1020
cgctttaatc gtggattaca ccggtattta taaagcggat attggtatta aagatggcaa 1080
aatcgctggc attggtaaag gcggtaacaa agacatgcaa gatggcgtta aaaacaatct 1140
tagcgtaggt cctgctactg aagccttagc cggtgaaggt ttgatcgtaa cggctggtgg 1200
tattgacaca cacatccact tcatttcacc ccaacaaatc cctacagctt ttgcaagcgg 1260
tgtaacaacc atgattggtg gtggaaccgg tcctgctgat ggcactaatg cgactactat 1320
cactccaggc agaagaaatt taaaatggat gctcagagcg gctgaagaat attctatgaa 1380
tttaggtttc ttggctaaag gtaacgcttc taacgatgcg agcttagccg atcaaattga 1440
agccggtgcg attggctttg caattcacga agactggggc accactcctt ctgcaatcaa 1500
tcatgcgtta gatgttgcgg acaaatacga tgtgcaagtc gctatcgcca cagacacttt 1560
gaatgaagcc ggttgtgtag aagacactat ggctgctatt gctggacgca ctatgcacac 1620
tttccacact gaaggcgctg gcggcggaca cgctcctgat attattaaag tagccggtga 1680
acacaacatt cttcccgctt ccactaaccc caccatccct ttcaccgtga atacagaagc 1740
agagcacatg gacatgctta tggtgtgcca ccacttggat aaaagcatta aagaagatgt 1800
tcagttcgct gattcaagga tccgccctca aaccattgcg gctgaagaca ctttgcatga 1860
catggggatt ttctcaatca ccagttctga ctctcaagcg atgggccgtg tgggtgaagt 1920
tatcactaga acttggcaaa cagctgacaa aaacaagaaa gaatttggcc gcttgaaaga 1980
agaaaaaggc gataacgaca acttcaggat caaacgctac ttgtctaaat acaccattaa 2040
cccagcgatc gctcatggga ttagcgagta tgtaggttca gtagaagtgg gcaaagtggc 2100

```
tgacttggta ttgtggagtc cagcattctt tggcgtgaaa cccaacatga tcatcaaagg 2160
cggattcatt gcgttaagcc aaatgggcga tgcgaacgct tctatcccta ccccacaacc 2220
ggtttattac agagaaatgt tcgctcatca tggtaaagct aaatacgatg caaacatcac 2280
ttttgtgtct caagcggctt atgacaaagg cattaaagaa gaattaggac ttgaaagaca 2340
agtgttgccg gtaaaaaatt gcagaaatat cactaaaaaa gacatgcaat tcaacgacac 2400
taccgctcac attgaagtca atcctgaaac ttaccatgtg ttcgtggatg gcaaagaagt 2460
aacttctaaa ccagccaata aagtgagctt ggcgcaactc tttagcattt tctaggattt 2520
tttaggagca acgctcctta gatccccggg aattggggat ccgctagccc gcctaatgag 2580
cgggcttttt tttctcgggc agcgttgggt cctggccacg ggtgcgcatg atcgtgctcc 2640
tgtcgttgag gacccggcta ggctggcggg gttgccttac tggttagcag aatgaatcac 2700
cgatacgcga gcgaacgtga agcgactgct gctgcaaaac gtctgcgacc tgagcaacaa 2760
catgaatggt cttcggtttc cgtgtttcgt aaagtctgga aacgcggaag tcagcgctct 2820
tccgcttcct cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg agcggtatca 2880
gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc aggaaagaac 2940
atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt 3000
ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg 3060
cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc cctcgtgcgc 3120
tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cctttctccc ttcgggaagc 3180
gtggcgcttt ctcaatgctc acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc 3240
aagctgggct gtgtgcacga accccccgtt cagcccgacc gctgcgcctt atccggtaac 3300
tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc agccactggt 3360
aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa gtggtggcct 3420
aactacggct acactagaag gacagtattt ggtatctgcg ctctgctgaa gccagttacc 3480
ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt 3540
tttttgtttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga agatcctttg 3600
atcttttcta cggggtctga cgctcagtgg aacgaaaact cacgttaagg gattttggtc 3660
atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg aagttttaaa 3720
tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgctt aatcagtgag 3780
gcacctatct cagcgatctg tctatttcgt tcatccatag ttgcctgact ccccgtcgtg 3840
tagataacta cgatacggga gggcttacca tctggcccca gtgctgcaat ga tac cgc 3898
                                                          Tyr Arg
                                                           1

gag acc cac gct cac cgg ctc cag att tat cag caa taa acc agc cag    3946
Glu Thr His Ala His Arg Leu Gln Ile Tyr Gln Gln     Thr Ser Gln
        5                   10                      15

ccg gaa ggg ccg agc gca gaa gtg gtc ctg caa ctt tat ccg cct cca    3994
Pro Glu Gly Pro Ser Ala Glu Val Val Leu Gln Leu Tyr Pro Pro Pro
        20                  25                  30

tcc agt cta tta att gtt gcc ggg aag cta gag taa gta gtt cgc cag    4042
Ser Ser Leu Leu Ile Val Ala Gly Lys Leu Glu     Val Val Arg Gln
    35                  40                      45

tta ata gtt tgc gca acg ttg ttg cca ttg ctg cag gca tcg tgg tgt    4090
Leu Ile Val Cys Ala Thr Leu Leu Pro Leu Leu Gln Ala Ser Trp Cys
    50                  55                  60

cac gct cgt cgt ttg gta tgg ctt cat tca gct ccg gtt ccc aac gat    4138
His Ala Arg Arg Leu Val Trp Leu His Ser Ala Pro Val Pro Asn Asp
```

```
 65                  70                  75                  80

caa ggc gag tta cat gat ccc cca tgt tgt gca aaa aag cgg tta gct    4186
Gln Gly Glu Leu His Asp Pro Pro Cys Cys Ala Lys Lys Arg Leu Ala
                85                  90                  95

cct tcg gtc ctc cga tcg ttg tca gaa gta agt tgg ccg cag tgt tat    4234
Pro Ser Val Leu Arg Ser Leu Ser Glu Val Ser Trp Pro Gln Cys Tyr
            100                 105                 110

cac tca tgg tta tgg cag cac tgc ata att ctc tta ctg tca tgc cat    4282
His Ser Trp Leu Trp Gln His Cys Ile Ile Leu Leu Leu Ser Cys His
        115                 120                 125

ccg taa gat gct ttt ctg tga ctg gtg agt act caa cca agt cat tct    4330
Pro     Asp Ala Phe Leu     Leu Val Ser Thr Gln Pro Ser His Ser
        130                     135                 140

gag aat agt gta tgc ggc gac cga gtt gct ctt gcc cgg cgt caa cac    4378
Glu Asn Ser Val Cys Gly Asp Arg Val Ala Leu Ala Arg Arg Gln His
        145                 150                 155

ggg ata ata ccg cgc cac ata gca gaa ctt taa aag tgc tca tca ttg    4426
Gly Ile Ile Pro Arg His Ile Ala Glu Leu     Lys Cys Ser Ser Leu
    160                 165                     170

gaa aac gtt ctt cgg ggc gaa aac tct caa gga tct tac cgc tgt        4471
Glu Asn Val Leu Arg Gly Glu Asn Ser Gln Gly Ser Tyr Arg Cys
    175                 180                 185

tga gat cca gtt cga tgt aac cca ctc gtg cac cca act gat ctt cag    4519
    Asp Pro Val Arg Cys Asn Pro Leu Val His Pro Thr Asp Leu Gln
        190                 195                 200

cat ctt tta ctt tca cca gcg ttt ctg ggt gag caa aaa cag gaa ggc    4567
His Leu Leu Leu Ser Pro Ala Phe Leu Gly Glu Gln Lys Gln Glu Gly
    205                 210                 215

aaa atg ccg caa aaa agg gaa taa ggg cga cac gga aat gtt gaa tac    4615
Lys Met Pro Gln Lys Arg Glu     Gly Arg His Gly Asn Val Glu Tyr
220                 225                     230

tca tac tct tcc ttt ttc aat att att gaa gca ttt atc agg gtt att    4663
Ser Tyr Ser Ser Phe Phe Asn Ile Ile Glu Ala Phe Ile Arg Val Ile
235                 240                 245                 250

gtc tca tga gcg gat aca tat ttg aat gta ttt aga aaa ata aac aaa    4711
Val Ser     Ala Asp Thr Tyr Leu Asn Val Phe Arg Lys Ile Asn Lys
                255                 260                 265

tag ggg ttc cgc gca cat ttc ccc gaa aag tgc cac ctg acg tct aag    4759
```

```
    Gly Phe Arg Ala His Phe Pro Glu Lys Cys His Leu Thr Ser Lys
                    270                 275                 280

aaa cca tta tta tca tgacattaa cct ata aaa ata ggc gta tca cga ggc 4810
Lys Pro Leu Leu Ser           Pro Ile Lys Ile Gly Val Ser Arg Gly
                285                          290

cct ttc gtc ttc aa                                               4824
Pro Phe Val Phe
295
```

<210> 20
<211> 14
<212> PRT
<213> Escherichia coli

<400> 20

```
Tyr Arg Glu Thr His Ala His Arg Leu Gln Ile Tyr Gln Gln
 1               5                  10
```

<210> 21
<211> 30
<212> PRT
<213> Escherichia coli

<400> 21

```
Thr Ser Gln Pro Glu Gly Pro Ser Ala Glu Val Val Leu Gln Leu Tyr
 1               5                  10                  15
Pro Pro Pro Ser Ser Leu Leu Ile Val Ala Gly Lys Leu Glu
            20                  25                  30
```

<210> 22
<211> 85
<212> PRT
<213> Escherichia coli

<400> 22

```
Val Val Arg Gln Leu Ile Val Cys Ala Thr Leu Leu Pro Leu Leu Gln
 1               5                  10                  15
Ala Ser Trp Cys His Ala Arg Arg Leu Val Trp Leu His Ser Ala Pro
            20                  25                  30
Val Pro Asn Asp Gln Gly Glu Leu His Asp Pro Pro Cys Cys Ala Lys
        35                  40                  45
Lys Arg Leu Ala Pro Ser Val Leu Arg Ser Leu Ser Glu Val Ser Trp
    50                  55                  60
Pro Gln Cys Tyr His Ser Trp Leu Trp Gln His Cys Ile Ile Leu Leu
65                  70                  75                  80
Leu Ser Cys His Pro
```

<210> 23
<211> 4
<212> PRT
<213> Escherichia coli

<400> 23
Asp Ala Phe Leu
1

<210> 24
<211> 35
<212> PRT
<213> Escherichia coli

<400> 24
Leu Val Ser Thr Gln Pro Ser His Ser Glu Asn Ser Val Cys Gly Asp
1 5 10 15
Arg Val Ala Leu Ala Arg Arg Gln His Gly Ile Ile Pro Arg His Ile
20 25 30
Ala Glu Leu
35

<210> 25
<211> 20
<212> PRT
<213> Escherichia coli

<400> 25
Lys Cys Ser Ser Leu Glu Asn Val Leu Arg Gly Glu Asn Ser Gln Gly
1 5 10 15
Ser Tyr Arg Cys
20

<210> 26
<211> 38
<212> PRT
<213> Escherichia coli

<400> 26
Asp Pro Val Arg Cys Asn Pro Leu Val His Pro Thr Asp Leu Gln His
1 5 10 15
Leu Leu Leu Ser Pro Ala Phe Leu Gly Glu Gln Lys Gln Glu Gly Lys
20 25 30
Met Pro Gln Lys Arg Glu
35

<210> 27
<211> 26
<212> PRT
<213> Escherichia coli

<400> 27
Gly Arg His Gly Asn Val Glu Tyr Ser Tyr Ser Ser Phe Phe Asn Ile
1   5   10   15
Ile Glu Ala Phe Ile Arg Val Ile Val Ser
            20   25

<210> 28
<211> 13
<212> PRT
<213> Escherichia coli

<400> 28
Ala Asp Thr Tyr Leu Asn Val Phe Arg Lys Ile Asn Lys
1   5   10

<210> 29
<211> 20
<212> PRT
<213> Salmonella typhimurium

<400> 29
Gly Phe Arg Ala His Phe Pro Glu Lys Cys His Leu Thr Ser Lys Lys
1   5   10   15
Pro Leu Leu Ser
            20

<210> 30
<211> 13
<212> PRT
<213> Salmonella typhimurium

<400> 30
Pro Ile Lys Ile Gly Val Ser Arg Gly Pro Phe Val Phe
1   5   10

<210> 31
<211> 31
<212> DNA
<213> Helicobacter pylori

<400> 31

tagggaattc tcatgaaact caccccaaaa g 31

<210> 32
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 32
gccaacttag cttcctttcg gg 22

<210> 33
<211> 34
<212> DNA
<213> Helicobacter pylori

<400> 33
tctactgcag gatccaaaat gctaaagagt tgcg 34

<210> 34
<211> 21
<212> DNA
<213> Salmonella typhimurium

<400> 34
tcaaatggta ccccttgctg a 21

<210> 35
<211> 20
<212> DNA
<213> Salmonella typhimurium

<400> 35
tattccggaa cttcgcgtta 20

<210> 36
<211> 23
<212> DNA
<213> Helicobacter pylori

<400> 36
tgtttcctga tgggactaaa ctc 23

<210> 37
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 37
accaggaact aatttaccat tg 22

<210> 38

<211> 21
<212> DNA
<213> Helicobacter pylori

<400> 38
ttgattgaca ttggcggtaa c 21

<210> 39
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 39
gttgtctgct tgtctatcaa cc 22

<210> 40
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 40
ggtggcggta aaaccctaag ag 22

<210> 41
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 41
ctttgctagg gttgttagat tg 22

<210> 42
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 42
aatccctaca gcttttgcaa gc 22

<210> 43
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 43
gtgccatcag caggaccggt tc 22

<210> 44
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 44
atcgccacag acactttgaa tg 22

<210> 45
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 45
tagcagccat agtgtcttct ac 22

<210> 46
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 46
tgaagacact ttgcatgaca tg 22

<210> 47
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 47
tgagagtcag aactggtgat tg 22

<210> 48
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 48
catgatcatc aaaggcggat tc 22

<210> 49
<211> 23
<212> DNA
<213> Helicobacter pylori

<400> 49
gaagcgttcg catcgcccat ttg 23

<210> 50
<211> 22
<212> DNA
<213> Helicobacter pylori

<400> 50
tcgtggatgg caaagaagta ac 22

<210> 51
<211> 20
<212> DNA
<213> Helicobacter pylori

<400> 51
gcgccaagct cactttattg 20

<210> 52
<211> 22
<212> DNA
<213> Salmonella typhimurium

<400> 52
caacgacagg agcacgatca tg 22